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Zusammenfassung 
Die Chronisch myeloische Leukämie (CML) ist eine Krankheit des 
hämatopoetischen Systems, welche durch die Expression von BCR-ABL1 ausgelöst 
wird. Dieses Onkoprotein ist eine konstitutiv aktive Protein-Tyrosinkinase (PTK), 
welche in Zellen Signalwege anschaltet, die unkontrolliertes Wachstum und Überleben 
steuern. Aus diesem Grund kann die CML mit spezifischen Tyrosinkinase-Inhibitoren 
(TKI) behandelt werden, die die Funktion von BCR-ABL1 hemmen. Imatinib, der erste 
TKI der in der Klinik Anwendung fand, hat die Therapie der CML revolutioniert: Die 
Patienten hatten gute Ansprechraten und viele ein gutes Langzeitüberleben mit 
vergleichsweise wenig Nebenwirkungen. Die Einführung von Nilotinib, eines noch 
potenteren Zweit-Generationen-TKI führte zu einem weiter verbesserten Wirkprofil mit 
schnellerem und tieferem Ansprechen. Ein Teil der Patienten wird voraussichtlich die 
Therapie absetzen können und trotzdem in therapiefreier Remission bleiben. 
Gegenstand aktueller klinischen Studien ist die Optimierung der Therapie und die 
genauere Untersuchung der Voraussetzungen für ein erfolgreiches Absetzen der TKI. 
Es ist bereits bekannt, dass ein besonders schnelles Erreichen einer anhaltenden, 
tiefen molekularen Remission sich günstig auf eine funktionelle Heilung auswirkt. Aus 
diesem Grund ist es von großem Interesse, die molekularen Mechanismen besser zu 
verstehen, welche das Erreichen der tiefen molekularen Remission beeinflussen. 
Protein-Tyrosinphosphatasen (PTPs) sind die Gegenspieler der PTK, indem sie 
Phosphotyrosin-Reste hydrolysieren. Auch BCR-ABL1 wird durch PTPs reguliert. 
Entspechend können PTPs auch das Ansprechen auf TKI beeinflussen. Der Beitrag 
einzelner PTPs, insbesondere bei einer Therapie mit TKI der zweiten Generation, ist 
jedoch noch nicht bekannt, und sollte in dieser Arbeit untersucht werden. 
Im ersten Teil der vorliegenden Arbeit wurde eine qRT-PCR Plattform etabliert und 
das mRNA-Expressionsniveau von 38 ausgewählten PTPs im peripheren Blut von 66 
neu diagnostizierten CML Patienten bestimmt. Diese Expressionsspiegel wurden dann 
mit dem individuellen Nilotinib-Ansprechen der einzelnen Patienten korreliert. Dies 
erfolgte anhand von Daten, die in der regelmäßigen Kontrolle des  Therapieverlaufs auf 
molekularer Ebene erhalten wurden: Die Menge an BCR-ABL1 Gentranskript wird 
bestimmt und bezugnehmend auf eine „Internationale Skala“ (BCR-ABL1IS) 
angegeben. Das Erreichen, oder Nicht-Erreichen der tiefen molekularen Remission 
(MR4, BCR-ABL1IS ≤ 0.01 %) nach 9 Monaten Nilotinib-Behandlung wurde mit dem 
individuellen Expressionsspiegel der PTPs verglichen. Patienten mit einem hohen 
Expressionsniveau von PTPRA, PTPRC, PTPRG, PTPRM und PTPN13 zu Beginn der 
Therapie hatten eine signifikant höhere Wahrscheinlichkeit, nach 9 Monaten eine MR4 
zu erreichen. Dies legte nahe, dass diese PTPs die Sensitivität der TKI Behandlung 
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positiv beeinflussen könnten. Aus diesem Grund, wurden im zweiten Teil der Arbeit 
ausgewählte PTPs, PTPRC und PTPRG, weiter in funktionellen Analysen untersucht. 
Zusätzlich haben wir auch PTPN6 tiefergehend untersucht, da für diese PTP bereits 
beschrieben wurde, dass sie die Empfindlichkeit für Imatinib beeinflussen kann. Es 
wurden Zelllinien hergestellt, in denen der PTP Expressionsspiegel durch 
Überexpression oder CRISRP/Cas9 vermittelten „Knockout (KO)“ verändert wurde. 
Diese Zellen wurden zur Bestimmung des IC50 von Nilotinib, Imatinib und Dasatinib, 
eines weiteren Zweit-Generationen-TKI, genutzt. Für PTPN6 konnten wir weder durch 
Überexpression, noch durch KO eine nennenswerte Änderung des IC50 aller drei TKIs 
feststellen. Unsere Daten sprechen deutlich  gegen einen,  früher von anderen 
vorgeschlagenen, Einfluss von PTPN6 auf die TKI-Wirkung. Der KO von PTPRC und 
die Überexpression von PTPRG jedoch führten zu signifikante Änderungen im IC50 für 
die Inhibitoren Nilotinib und Imatinib. Für Dasatinib war der IC50 durch die Änderung 
der PTP-Spiegel jedoch zumeist nicht  signifikant verändert.  
Im dritten Teil der Arbeit wurden die molekularen Mechanismen der PTP-Wirkung 
weiter analysiert. Wir untersuchten zunächst den Einfluss der PTPs auf die BCR-ABL1-
vermittelte Zell-Transformation mit Hilfe von Koloniebildungs-Experimenten. Die 
Bildung von Kolonien wurde durch den KO von PTPRC sowie die Überexpression von 
PTPRG signifikant reduziert. Diese Befunde identifizierten PTPRC als potenziellen 
Verstärker und PTPRG als hemmenden Faktor der Transformation durch BCR-ABL1. 
Die Analyse verschiedener  Signalwege zeigte Gemeinsamkeiten zwischen der 
Änderung durch die Nilotinib Behandlung einerseits und dem KO von PTPRC, 
beziehungsweise der Überexpression von PTPRG andererseits. Wir beobachteten eine 
gleichsinnige verminderte Aktivierung von Kinasen der SRC-Familie (SFKs) und eine 
Erhöhung der Spiegel des Zellzyklus-Inhibitors p27. Es ist wahrscheinlich, dass diese 
beiden Signalwege an der Verminderung der TKI-Empfindlichkeit sowie der BCR-ABL1 
vermittelten Transformation beteiligt sind. Konsistent mit einer Bedeutung dieser 
veränderten Signalereignisse, wurde die Sensitivität gegenüber dem dualen BCR-
ABL1/SFK-Inhibitor Dasatinib durch PTPRC und PTPRG wenig beeinflusst. Weiterhin 
konnte eine Kombinations-Behandlung von Nilotinib mit dem Phosphoinositid-3-
Kinase-Inhibitor Idelalisib, welcher einen Anstieg von p27 in den behandelten Zellen 
hervorruft, die Wirkung von Nilotinib verstärken.  
Zusammengefasst konnte gezeigt werden, dass PTPs, im besonderen PTPRC und 
PTPRG, einen Beitrag zum Behandlungs-Erfolg auch in Nilotinib-behandelten 
Patienten leisten. Die Befunde zum Wirkungsmechanismus könnten genutzt werden, 
um die Therapie weiter zu verbessern. PTPs sollten weiterhin als mögliche 
prognostische Marker für das Therapieansprechen evaluiert werden. 
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Summary 
Chronic myeloid leukemia (CML) is a disease of the hematopoietic system, caused 
by the expression of the constitutively active oncogenic fusion protein-tyrosine kinase 
(PTK) BCR-ABL1. This kinase triggers signaling cascades that lead to uncontrolled cell 
proliferation and survival. Therefore, treatment of CML is possible with specific 
tyrosine-kinase inhibitors (TKIs) targeting BCR-ABL1. Imatinib, the first TKI introduced 
in the clinic, has revolutionized CML therapy with excellent efficiency and long-term 
survival of responders with only little side-effects. The recent introduction of the more 
potent second-generation TKIs has led to even better therapeutic efficiency with faster 
and more complete responses, allowing some patients to stop treatment and remain in 
treatment-free remission. The optimization of the treatment regimens and the specific 
prerequisites to successfully stop treatment are currently addressed in several clinical 
studies. It is already known, that a fast and sustained deep molecular response is 
beneficial to achieve a functional cure. Therefore, molecular mechanisms promoting or 
delaying achievement of this state are of great interest and clinical relevance. 
Protein-tyrosine phosphatases (PTPs) are counter-acting the activity of PTKs by 
hydrolyzing phospho-tyrosines. By antagonizing the activity of the oncogenic PTK 
BCR-ABL1, PTPs may have an effect on TKI sensitivity and treatment response. The 
potential impact of specific PTPs on therapeutic response in CML patients treated with 
second-generation TKIs is currently unknown but may be clinically relevant. This issue 
was therefore addressed in the current thesis. 
In the first part of the thesis, we attempted to correlate the individual treatment 
response with the PTP-status in CML cells before the beginning of treatment. To this 
end, the mRNA expression levels of 38 selected PTPs were determined in total 
peripheral blood leukocytes in 66 newly diagnosed CML patients using a qRT-PCR 
platform that was newly developed in this project. The molecular response of the 
patients was regularly assessed during clinical monitoring by determination of BCR-
ABL1 transcript levels that are reported on an international scale (BCR-ABL1IS).  PTP 
mRNA-levels at the beginning of treatment were then correlated to whether or not the 
patient had reached a deep molecular response (MR4, BCR-ABL1IS ≤ 0.01 %) after 9 
months of nilotinib treatment. We found mRNA expression of PTPRA, PTPRC, 
PTPRG, PTPRM, and PTPN13 to be positively associated with a particularly good 
nilotinib treatment outcome. This finding indicated that these PTPs may affect TKI-
sensitivity at the cellular level. Therefore, in the second part of this thesis, PTPRC and 
PTPRG were selected for further functional analyses in cell line models. In addition, 
PTPN6, a PTP earlier reported as affecting imatinib treatment response, was included, 
although its expression was not found correlated with response in our patient dataset. 
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CRISPR/Cas9-mediated gene knockout (KO) or PTP over-expression were used to 
manipulate PTP expression levels in CML cell lines, and the impact on TKI response 
was measured by determination of potential changes of the IC50s for nilotinib, imatinib, 
and another second-generation inhibitor, dasatinib. In case of PTPN6, neither gene KO 
nor over-expression led to substantial changes in the IC50s of all tested TKIs, 
disproving a role of PTPN6 for the therapy response at least under our experimental 
conditions. In contrast, PTPRC and PTPRG had effects on TKI responses. A KO of 
PTPRC or the over-expression of PTPRG caused a significant reduction of the IC50s for 
nilotinib and imatinib whereas the IC50 for dasatinib was not significantly affected.  
In the third part of the thesis, the mechanisms potentially involved in the altered TKI 
responses in cells with genetically modified PTP levels were addressed. First, effects 
on BCR-ABL1 driven cell transformation were measured by analyzing colony forming 
capacity of the cell lines in methylcellulose. Indeed, both PTPRC and PTPRG had an 
impact. The colony-forming capacity was significantly reduced in PTPRC-KO cells as 
well as in PTPRG over-expressing cells, suggesting PTPRC as promoting, and PTPRG 
as attenuating BCR-ABL1 dependent transformation, respectively. Assessment of 
BCR-ABL1 signaling in immunoblotting experiments revealed common alterations in 
nilotinib-treated cells, and cells with PTPRC-KO or PTPRG over-expression. These 
comprised a reduction of SRC-family kinase (SFK)-activity and an elevation of the cell 
cycle inhibitor p27. It is possible that both events contribute to the observed 
phenotypes, namely promotion of TKI responses and attenuation of BCR-ABL1-
mediated transformation. Consistent with this interpretation, altered PTPRC or PTPRG 
levels had little effect on response to dasatinib, a dual BCR-ABL1/SFK inhibitor. 
Moreover, co-treatment of cells with TKI and idelalisib, a phosphoinositide 3-kinase 
inhibitor which promotes p27 accumulation, showed enhanced efficiency.  
Taken together, work presented in this thesis has shown that PTPs, especially 
PTPRC and PTPRG, contribute to treatment response to the second-generation TKI 
nilotinib, and that the knowledge of the mechanistic background may help to optimize 
therapeutic strategies. Expression of PTPs identified to be correlated with response 
may also be explored as possible prognostic markers in the future. 
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1 Introduction 
1.1 Chronic myeloid leukemia 
Chronic myeloid leukemia (CML) is a malignant disease based on an aberrant clonal 
proliferation of hematopoietic stem cells (HSCs). It is characterized by an elevated level 
of cells of the myeloid differentiation line, mainly granulocytes and their precursors. 
Main symptoms of the disease are fatigue, anemia, splenomegaly, abdominal 
discomfort, and episodes of infections, but patients may also be asymptomatic. The 
disease is often discovered during routine checkups or unrelated medical 
examinations. The CML progresses in three phases: chronic phase (CP), accelerated 
phase (AP), and blast crisis (BC), with the latter appearing similar to an acute 
leukemia.    
The first treatments were purely palliative, using arsenic (first reported in 1865), 
splenic irradiation, the cytostatic agents busulfan and hydroxyurea (HU), or 
combinations of different chemotherapeutics. It took more than one century to 
introduce the first curative therapy, the stem cell transplantation. In addition to that, the 
cytokine interferon-α (IFN-α), HU, the anti-metabolite cytarabine, or combinations of 
them were used as life-prolonging therapies (Hehlmann, 2005). Today, drugs are 
available that specifically target the molecular cause of CML: the BCR-ABL1 
oncoprotein. 
 
1.1.1 The Philadelphia chromosome and BCR-ABL1 
A chromosomal abnormality associated with “chronic granulocytic leukemia” (a 
different name for CML) was first described by Peter C. Nowell and David A. 
Hungerford in 1960 (Nowell & Hungerford, 1960a; Nowell & Hungerford, 1960b) which 
was later named “Philadelphia Chromosome” after the city in which both scientists had 
made this observation. It took until 1973, when Janet D. Rowley  identified this 
abnormality to be the consequence of  a reciprocal chromosomal translocation, today 
referred to as t(9;22)(q34;q11). It is the fusion product of a shortened chromosome 22 
and a part of the q-arm of chromosome 9 (Figure 1-1, A)(Rowley, 1973). 
In 1982, de Klein et al. found ABL1 (Abelson Murine Leukemia Viral Oncogene 
Homolog 1) to be translocated from chromosome 9 to chromosome 22 (de Klein, 
1982), and in 1984, Groffen et al. described the 5’ DNA region to which a major part of 
the ABL1 gene is fused as the breakpoint cluster region (BCR). This designation was 
chosen because they found different breakpoints in individual patient samples (Groffen, 
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1984). Later on, the fusion protein encoded by BCR and ABL1, BCR-ABL1, was 
identified as a constitutively active tyrosine kinase (Naldini, 1986).  
Not only the exact breakpoints of BCR but also those of the ABL1 gene are variable, 
with the ABL1 sequence usually breaking between exon 1 and 2, (“a2”) and in rare 
cases between exon 2 and 3 (“a3”). The BCR breakpoints are more variable and can 
be categorized in M-BCR (major), m-BCR (minor), µ-BCR (micro), and ν-BCR (nano) 
(Figure 1-1, B). The transcripts are named after the last exons of both genes that are 
included in the transcript. The most prevalent CML-associated transcripts are e13a2 
(also named “b2a2”) and e14a2 (“b3a2”) (Figure 1-1, B). These transcripts encode 
proteins that have a molecular mass of about 210 kDa (p210). The protein encoded by 
the transcript e1a2 is a 190 kDa protein, associated with Philadelphia positive ALL 
(acute lymphoblastic leukemia), a distinct disease with features different to that of CML.  
In the normal ABL1 protein, the N-terminus gets myristoylated. The myristoyl-moiety 
folds into a myristoyl-binding pocket close to the ABL1 C-terminus. This leads to an 
inactive kinase conformation and thereby autoinhibition of the ABL1-tyrosine kinase 
activity. In the BCR-ABL1 protein the N-terminus of ABL1 is replaced by the bulky BCR 
and consequently lacks myristoylation. Therefore the kinase cannot be autoinhibited 
and is constitutively active (Hantschel, 2003). This activity leads to transformation of 
cells: It causes growth factor-independent proliferation, and inhibits apoptosis. 
Expression of BCR-ABL1 in HSCs used for reconstitution of mouse bone marrow is 
sufficient to cause a CML-like phenotype, indicating that expression of BCR-ABL1 is 
the only lesion required for CML (Daley, 1990).  
Figure 1-1. (A) Overview of the 9;22 translocation leading to formation of the Philadelphia 
chromosome. (B) Scheme of the BCR and the ABL1 genes and the exemplary translocation 
leading to the e13a2 (“b2a2”) transcript, and expression of the respective protein with the N-
terminal BCR and the C-terminal ABL1 part. Figure layout adapted from “Grundkurs Hämatologie” 
(Hoffbrand, 2002), gene structures adapted from (Burmeister & Reinhardt, 2008), and BCR-ABL1 
protein domain structure adapted from (Reckel, 2017).  
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1.1.2 BCR-ABL1 signaling 
As indicated, the expression of BCR-ABL1 causes elevated cell proliferation, 
growth-factor-independent growth, and diminished apoptosis. This occurs via different 
signaling pathways. A simplified scheme of BCR-ABL1 signaling is provided in 
Figure 1-2.  
BCR-ABL1 can activate the MEK (MAP- and ERK kinase) / ERK (extracellular 
signal-regulated kinase) pathway, via activation of membrane associated Ras / Raf 
molecules, leading to cell proliferation. The PI3K (phosphatidylinositol-3-kinase) / AKT 
(v-akt murine thymoma viral oncogene homolog, also known as PKB, protein kinase B) 
pathway inhibits apoptosis by regulating Bcl-2 (B-cell lymphoma 2) proteins. It also 
leads to phosphorylation of the cell cycle inhibitor p27 (CDKN1B, cyclin-dependent 
kinase inhibitor 1B, also referred to as p27Kip1), causing its proteasomal degradation 
and thereby cell cycle progression (Roy & Banerjee, 2015). BCR-ABL1 can activate 
STAT5 (signal transducer and activator of transcription 5), either indirect via activation 
of Jak2 (Janus kinase 2) or SFK (SRC-family kinases) (Okutani, 2001; Weisberg, 2007; 
Schmidt & Wolf, 2009), or by direct phosphorylation (Hantschel, 2012). This leads to 
activation of STAT5 target genes, for example genes encoding anti-apoptotic proteins 
such as Bcl-2, promoting cell survival and proliferation. Also cytosolic SFK are 
Figure 1-2. Simplified scheme of BCR-ABL1 signaling. Green arrows indicate activation, red mark 
indicates induction of degradation. Orange arrows show general consequences of signaling 
pathways. For details see text.  
PI3K (phosphatidylinositol-3-kinase), AKT (v-akt murine thymoma viral oncogene homolog, also 
known as PKB, protein kinase B), p27 (CDKN1B, cyclin-dependent kinase inhibitor 1B, also 
referred to as p27
Kip1
), Jak2 (Janus kinase 2), STAT5 (signal transducer and activator of 
transcription 5), Bcl-2 (B-cell lymphoma 2), SFK (SRC-family kinases), MEK (MAP- and ERK 
kinase), ERK 1/2 (extracellular signal-regulated kinase). 
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activated by BCR-ABL1. These kinases are involved in multiple signaling pathways 
promoting cell proliferation and anti-apoptotic processes (Danhauser-Riedl, 1996; 
Ptasznik, 2004).  
Several key players that will be analyzed in some detail later in this thesis project 
are: ERK 1/2, STAT5, AKT, SFK, especially cSRC (cellular homologue to v-src 
expressed by Rous Sarcoma virus) and Lyn (Lck / Yes related novel tyrosine kinase), 
p27, and Bcl-2.  
BCR-ABL1 was also reported to affect DNA repair response pathways, leading to 
accumulation of mutations and additional chromosomal alterations (Cramer, 2008) 
further promoting CML progression or therapy failure (see below). Many of these 
pathways can cross-interact with each other, building a signaling network triggered by 
BCR-ABL1 and resulting in the CML phenotype. In all described signaling cascades, 
phosphorylations of different signaling proteins by protein kinases play an important 
role.  
The counter actors of protein-tyrosine kinases (PTKs), the protein-tyrosine 
phosphatases (PTPs), can de-phosphorylate target proteins of BCR-ABL1 (e. g. 
STAT5) or BCR-ABL1 itself and thereby interfere with the signaling cascades driven by 
the BCR-ABL1 oncogene (see chapter 1.2). 
 
1.1.3 CML diagnostics and monitoring 
The CML diagnostics are based on hematologic, cytogenetic, and molecular 
analyses. In the hematologic examination, peripheral blood is microscopically 
analyzed. The elevation of leukocytes with presence of immature precursors or even 
blasts can thereby be detected. To assure the CML diagnosis, cells of the bone marrow 
are also analyzed microscopically (criteria: higher cell density, elevation of leukocytes 
and their precursors, elevated levels of megakaryocytes) and with a chromosome 
banding or FISH (Fluorescence in situ hybridization) analysis of cell metaphases, 
assessing the presence of the characteristic Philadelphia chromosome or other 
chromosomal aberrations. In addition to these analyses, the presence and type of 
BCR-ABL1 transcript is determined by qualitative PCR (Polymerase-chain reaction). 
The knowledge of the specifically expressed BCR-ABL1 transcript is needed for correct 
disease monitoring under therapy. Therapy response can be observed directly in a 
blood or bone marrow sample, giving information on the hematologic or cytogenetic 
response. Once the complete cytogenetic remission (CCyR) is achieved (no 
Philadelphia chromosomes detectable in at least 20 analyzed bone marrow cell-
metaphases), only more sensitive molecular detection methods can be used to further 
monitor treatment efficiency. Therefore, molecular monitoring in peripheral blood 
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samples after erythrocyte lysis has been established, using a standardized RT-qPCR 
(reverse transcription quantitative PCR) assay to determine the quantitative mRNA 
(messenger RNA) ratio of BCR-ABL1 and ABL1. Today, this is the preferred method to 
monitor treatment response in CML patients since it is less invasive that bone marrow 
analysis and can detect even lower levels of residual disease. In the IRIS Study 
(International Randomized Study of Interferon and STI571 (Imatinib)), the RT-qPCR 
analysis was performed in 3 different laboratories, showing a high variability of results 
that needed to be standardized to be comparable. For this reason, the International 
Scale (IS) was developed, by analyzing a set of 30 individual patient samples in all 
three laboratories, and normalizing all subsequent results to this IRIS-baseline as 
“100 % BCR-ABL1IS“. This baseline is also the reference for the definitions of “major” 
and “deep” molecular response as outlined in Table 1-1 (Hughes, 2003). 
Since the initially used 30 reference samples were limited, the use of a general 
laboratory-specific conversion factor was initiated. This factor is derived by regular re-
analysis of 20 – 30 reference samples, and calculation of a laboratory specific 
conversion factor with the measured results to obtain comparable values in all different 
laboratories (Cross, 2015).  
Evaluation of clinical trials using the BCR-ABL1IS led to the definition of therapy 
milestones by the European LeukemiaNET (ELN) to give indications for optimal 
response, warning, or failure of treatment, according to the de- or increase of BCR-
ABL1 of each individual patient under therapy (Baccarani, 2013).  
 
 
 
 
 
 
  
*)  100 % is defined as the IRIS-standardized baseline  
 (Hughes, 2003). 
**)  These BCR-ABL1
IS
 levels correspond to the indicated  
 cytogenetic responses when measured in independent analyses. 
Table 1-1. Stages of molecular responses to CML therapy on 
international scale (IS). 
Response BCR-ABL1
IS
 
CML cells diagnosis  100 % *  
Partial cytogenetic response  PCyR  10 % **  
Complete cytogenetic response  CCyR  1 % **  
Major molecular response  MMR  0.1 %  
Deep molecular response  MR
4
  0.01 %  
Deep molecular response  MR
4.5 
 0.0032 %  
Deep molecular response  MR
5
  0.001 %  
No detectable BCR-ABL1 transcripts  <0.001 %  
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1.1.4 Imatinib – the first targeted therapy in CML 
The knowledge that the driver of CML cell proliferation, BCR-ABL1, is a 
constitutively active tyrosine kinase prompted the development of tyrosine-kinase 
inhibitors (TKIs) to specifically treat CML. The first TKI developed to target BCR-ABL1 
was Imatinib (STI571, Gleevec, Novartis, Figure 1-3, A). Imatinib blocks the ATP 
binding-site of the ABL1 kinase by binding to the kinase in its inactive conformation. It 
was initially shown to effectively kill BCR-ABL1-positive cell lines and to reduce dose-
dependently tumor formation of engineered 32D cells expressing BCR-ABL1 (p210) in 
syngenic C3H/HEJ mice (Druker, 1996). 
Based on these promising preclinical findings, clinical trials started in 1998, showing 
the superiority of Imatinib over IFN-α treatment of CML in all clinical phases, leading to 
the approval by the US Food and Drug Administration (FDA) in May 2001, and shortly 
afterwards also in Germany (Hehlmann, 2005). Just recently, the long term analysis of 
the IRIS (International Randomized Study of IFN and STI571)-study has shown that the 
imatinib treatment-efficiency has persisted over more than 10 years, without cumulative 
or late toxic effects (Hochhaus, 2017). The median age of CML patients reported in this 
study was 50 years, with a survival rate of more than 80 % after 10-years follow up. 
Despite the great success of imatinib treatment, not all CML patients benefit from 
treatment to the same extent. Some patients do not respond well to the TKI therapy 
from the beginning (primary resistance) or suffer from resistance development and 
disease progression under therapy (secondary resistance, relapse). There are two 
main scenarios leading to imatinib resistance: on the one hand, mutations in the BCR-
Figure 1-3. Three TKIs used in this thesis. Top: Surface representations of crystal structures of 
ABL1 kinase in complex with imatinib (A), nilotinib (B), or dasatinib (C). Residues from the 
nucleotide-binding loop (P-loop) and activation loop (A-loop) are omitted from the surface 
calculation for clarity. Below, the molecular structures of the TKIs. Adapted from (Weisberg, 2007).  
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ABL1 protein, leading to conformational changes that decrease the binding affinity of 
imatinib or destabilize the inactive conformation (e. g. mutations of Gly 250, Tyr 253, 
Met 351), or mutations that create direct steric hindrances that prevent binding of 
imatinib (e. g. Thr 315) are found. On the other hand, clonal evolution of leukemic stem 
cells with acquisition of additional mutations and activation of BCR-ABL1-independent 
pathways can lead to disease progression (Hehlmann, 2005; Weisberg, 2007).  
 
1.1.5 Resistance mechanisms and new therapy options 
As mentioned, the reasons for primary resistance or suboptimal therapy response 
can in some patients be directly linked to BCR-ABL1 mutations. In addition, genomic 
amplification or over-expression of BCR-ABL1 can cause TKI resistance. In other 
patients, BCR-ABL1 independent mechanisms are the cause of refractory disease or 
relapse. These may involve the acquisition of additional chromosomal aberrations 
activating BCR-ABL1 independent signal transduction pathways, or general 
pharmacokinetic factors resulting in reduced drug availability (Hochhaus, 2002; Cross, 
2015).  
One way of overcoming BCR-ABL1-dependent resistance is the development of 
new drugs, targeting also imatinib resistant BCR-ABL1 mutants. Today, two more 
compounds are approved for first-line treatment of CML that can overcome imatinib 
resistance in many cases: nilotinib (AMN107, Tasigna, Novartis, Figure 1-3, B) and 
dasatinib (BMS-354825, Sprycel, Bristol-Myers Squibb, Figure 1-3, C). Nilotinib is a 
derivative of imatinib, developed by rational drug design. It is about 30-fold more potent 
in inhibiting ABL1 kinase, has improved specificity, and inhibits 32 of 33 mutant BCR-
ABL1 forms in vitro, that are resistant to imatinib. Similar to imatinib, it also binds the 
inactive kinase conformation (Weisberg, 2007). Interestingly, formation of the inactive 
kinase conformation requires de-phosphorylation of BCR-ABL1. This may link the 
efficiency of imatinib and nilotinib to the status of PTPs, since they are responsible for 
the de-phosphorylation of BCR-ABL1, and thereby indirectly influence the TKI binding. 
Dasatinib is a highly potent inhibitor of cSRC and SFK, also targeting BCR-ABL1. It 
binds, in contrast to imatinib and nilotinib, to the active conformation of the ABL1 
kinase. Dasatinib has been shown to inhibit 21 of 22 mutant forms, which are resistant 
to imatinib (Weisberg, 2007).        
In addition to these first-line treatment options, the inhibitors bosutinib (AKI-606, 
Bosulif, Pfizer) and ponatinib (AP24534, Iclusig, Ariad Pharmaceuticals) are available 
as second-line treatment. Ponatinib is especially used for treatment of the Thr 315 Ile 
(T315I) mutation of BCR-ABL1 at any stage, since this mutation causes resistance to 
the four other inhibitors. 
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As mentioned above, wild type ABL1 kinase is autoinhibited by binding of a 
myristoyl-moiety to a myristoyl-pocket, inducing the formation of an inactive kinase 
conformation. This mechanism can be mimicked by administration of allosteric 
inhibitors that bind to this pocket, and induce the conformational change, leading to 
inhibition of the kinase. One such inhibitor is Asciminib (ABL001, Novartis). It was 
already tested in a phase I clinical trial, with first results published recently, showing 
activity in heavily pretreated CML patients (Wylie, 2017). ATP-competitive inhibitors 
and this allosteric inhibitor show distinct patterns of activity against BCR-ABL1 with 
resistance mutations, providing one more tool to overcome resistance if administered 
as single drug or in combination therapies. 
Since more than 30 years, different CML risk scores based on clinical parameters 
have been established and improved to predict treatment outcome or prognosis of 
long-term survival by evaluating clinical parameters at diagnosis. These include the 
Sokal score (Sokal, 1984), Hasford score (Hasford, 1998), EUTOS score (Hasford, 
2011), or ELTS score (Pfirrmann, 2016). Also, the specific BCR-ABL1 transcript 
expressed in the leukemic cells does have an influence on treatment response (Jain, 
2016). In addition, the efficiency of the individual molecular and cytogenetic response 
after 3 and 6 months of TKI treatment can predict long-term progression-free and 
overall survival (Hanfstein, 2012; Hanfstein, 2014). Up to now, not many BCR-ABL1-
independent resistance mechanisms are known (La Rosee & Deininger, 2010; Ernst & 
Hochhaus, 2012). To further elucidate such mechanisms, a number of genome wide 
expression analyses comparing well-responding to poor-responding patients were 
performed to identify genes and pathways potentially contributing to treatment outcome 
(reviewed by (Schmidt & Wolf, 2009)). These studies revealed interesting gene sets, 
that are associated with treatment response, but findings are inconsistent, and the 
types of analyzed patient samples are varying among the studies. A just recently 
published study presented a protein panel that was associated with molecular 
response of CML patients under imatinib treatment (Alaiya, 2016). 
 Almost all published studies on association of treatment response with gene 
expression so far are based on imatinib therapy. Therefore, there is a need for such 
studies in nilotinib-treated patients. In this thesis, I focused on the role of PTPs for 
nilotinib response.  
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1.1.6 Treatment-free remission and functional cure 
For many years it was believed, that CML patients need to be treated lifelong with 
TKIs in order to control the disease. However, based on the continuous improvement of 
CML treatment and management, a newly emerged goal is to find patients eligible to 
stop treatment and still remain in treatment-free remission (TFR). Previous 
observations have suggested that this may be possible for a sub-set of patients. In 
2002, some patients with undetectable disease after IFN-α treatment stopped the 
medication and remained in molecular remission (Mahon, 2002). In the STIM-study 
(Stop Imatinib), about 40 % of imatinib-treated patients stayed in TFR when treatment 
was stopped after 2 years of deep molecular response (Mahon, 2010). The initial 
studies showed that fast and durable deep molecular responses to TKI were 
associated with a higher probability of remaining in remission after discontinuation of 
TKIs. The second-generation TKI nilotinib is leading to much faster and deeper 
molecular remissions compared to imatinib (ENESTnd study)(Hochhaus, 2016), 
suggesting that a high fraction of patients may achieve a TFR. Therefore, one new 
study sponsored by the University of Jena, the TIGER study (Tasigna / Interferon in 
Germany, NCT01657604) is aiming to discontinue the TKI treatment after > 24 months 
of nilotinib treatment and > 12 months of MR4 or better. In addition, the study is re-
introducing the “classical” IFN-α treatment to find out, if the number of patients with a 
functional cure can be further enhanced by this combination treatment. The patients 
are randomized to either receive nilotinib alone, or nilotinib in combination with PEG-
IFN-α2b (pegylated interferon α2b). All patient samples analyzed in this thesis are from 
participants of this study. 
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1.2 Protein-tyrosine phosphatases 
1.2.1 The PTP families 
PTPs are the counter-actors of PTKs, hydrolyzing phospho-tyrosines and thereby 
removing the tyrosine-phosphorylation from their target proteins. For a long time it was 
believed, that the PTPs are de-phosphorylating substrates constitutively with little 
regulation of activity, leaving the regulating part to the PTKs (Tonks, 2013). Later 
analyses revealed that the enzymatic activity of the PTPs is much higher than that of 
PTKs, causing the need to tightly regulate their catalytic activity, because otherwise no 
phosphorylation would occur in the cells. Indeed, the precise regulations of PTPs via 
many different mechanisms and their rather specific functions have meanwhile been 
established. 
The human genome harbors 125 genes encoding the family of PTPs. The PTP 
proteins are  determined by one of the following features: i) the presence of a PTP 
domain, ii) the presence of the CxxxxxR signature motif in a non-PTP domain, iii) the 
evidence of actual tyrosine phosphatase activity, or iiii) showing high sequence 
similarity to proteins with known tyrosine-phosphatase activity (Alonso & Pulido, 2016). 
Of these 125 proteins, only about 40 exclusively target phospho-tyrosines, while others 
target in addition, or exclusively e. g. phospho-serines, phospho-threonines, 
phosphatidyl-inositols, mRNA cap structures, or are even catalytically inactive (Alonso, 
2004; Alonso & Pulido, 2016). 
In 2004, Alonso et al. introduced a classification of the PTPs into 4 families 
according to the amino acid sequence of their catalytic domains. This classification was 
further adjusted in 2016, now proposing 3 main families to which the members were 
assigned according to their nucleophilic catalytic residue (Cys, Asp, or His) as 
summarized in Table 1-2. The cysteine based PTPs are the largest family (> 90 % of 
listed PTPs) and all 38 PTPs (chapter 3.1) analyzed in this thesis are members of this 
family. This large PTP family can again be sub-divided into 3 classes (Table 1-2). The 
class I cysteine-based PTP-family, that comprises the classical PTPs (sub-class I) and 
VH1-like (from vaccina virus) dual-specific PTPs (DUSPs, sub-class II). 35 of the 38 
PTPs analyzed in this thesis are members of these two sub-classes (Alonso, 2004; 
Julien, 2011).  
The class II cysteine-based PTP family has only two members, one of them is the 
LMW-PTP (ACP1, analyzed in this thesis). The three cell cycle regulators CDC25A, 
CDC25B, and CDC25C are the only members of the class III cysteine-based PTP 
family, with CDC25A and B being included in analyses in this thesis. Further details are 
outlined in Table 1-2.   
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1.2.2 Regulation of PTPs 
As already mentioned above, PTPs are not just simple housekeeping enzymes. The 
regulation of PTPs occurs at different levels: by differential expression in organs, 
tissues, and cells, by regulation of the sub-cellular localization, and by regulation of 
activity at the molecular level by different mechanisms e. g. by posttranslational 
modifications.   
Obviously, the differential expression can regulate the PTP function. There are 
PTPs which are ubiquitously expressed (e. g. SHP2 (PTPN11) or PTP1B (PTPN1)), 
and others which are selectively expressed and are induced (or silenced) upon 
differentiation of specific tissues, or as response to stimuli from outside of the cell. For 
example, the PTP DEP-1 (density enhanced phosphatase 1, PTPRJ) is up-regulated in 
some cell types when they reach high cell densities. In other cases, the expression of 
different PTP isoforms can be caused by the tissue-specific usage of different 
promoters for one PTP gene and, in case of the receptor like PTPs PTPRE and 
Abbreviations used: ACP (acid phosphatase), CDC (cell division cycle), DSP (dual-specific 
phosphatase), EYA (Eyes absent), HAD (haloacid dehalogenase), INPP (inositol polyphosphate 
phosphatases), LMW (Low molecular weight), MKP (MAPK phosphatases), MTM (myotubularin), 
NRPTP (non-receptor PTP), PALD (Paladin), PGM (phosphoglycerate mutase), PIP 
(phosphoinositide phosphate), PRL (Phosphatases of regenerating liver), PTEN (Phosphatase and 
Tensin homolog), RPTP (receptor-like phosphatase), SAC (from Saccharomyces cerevisiae), 
SSU72 (suppressors of sua7), TMEM (transmembrane protein), UBASH (ubiquitin-associated 
(UBA) and SRC homology 3 (SH3) domain-containing protein), VH (from vaccina virus).  
 
 
Table 1-2. PTP classes (Alonso, 2004; Alonso & Pulido, 2016). 
Main 
families  
# Sub-groups # Substrates 
Cysteine-
based  
Class I  
Sub-class I  Classic  37 
RPTPs  20 
pTyr, PIPs  
NRPTPs  17 
Sub-class II  VH1-like  64 
MKPs  11 
pTyr, pSer, pThr, 
PIPs, other  
Atypical DSPs  20 
Slingshots  3 
PRLs  3 
CDC14s  4 
PTEN-like  8 
MTMs  15 
Sub-class III  SACs  5    
 
PIPs  
Sub-class IV  PALD1  1    
 
unknown substrate  
Sub-class V  INPP4s  2    
 
PIPs  
Sub-class VI  TMEM55s  2    
 
PIPs  
Class II  
LMW-PTP  1    
 
pTyr  
SSU72  1    
 
pSer  
Class III CDC25s 3 
  
pTyr, pThr 
Aspartate-
based  
HAD  EYAs  4    
 
pTyr, pSer  
Histidine-
based  
PGM  UBASH3s  2    
 
pTyr  
Acid phosphatases  ACPs  3    
 
pTyr, pSer, pThr, 
other  
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PTPRR, that even results in the expression of either soluble, cytoplasmatic, or 
transmembranal PTP versions.  
The specific localization of PTPs to the different compartments of the cell or their 
recruitment to other proteins (either adapter or target proteins) likewise influences the 
PTP activity. For example, PTPN6 and PTPN11 are targeted to the plasma membrane 
by their SH2 domains. The C-terminus of PTPN6 additionally harbors a recognition-site 
for acidic phospholipids, targeting it to lipid rafts in T-lymphocytes, where it regulates T-
cell receptor signaling. Other domains like FERM, PDZ, or proline-rich domains can 
recruit cytoplasmatic PTPs to cell-cell or cell-matrix adhesion complexes. Likewise, the 
targeting to the ER, secretory vesicles, or to the nucleus is achieved by specific 
domains or targeting sequences. Alternative splicing may lead to PTP variants, that 
lack certain domains or targeting sequences, and thereby exhibit different specificity 
patterns (den Hertog, 2008).  
Besides the influence of expression or localization, the PTP proteins can undergo 
post-translational modifications. Interestingly, the PTPs themselves can be 
phosphorylated (serine-, threonine-, and tyrosine-phosphorylation) leading to 
conformational changes that either activate or inhibit the activity, or serve as binding-
sites for adapter molecules. This indicates that PTPs may also regulate each other’s 
activity. An important regulatory mechanism is the reversible oxidation of the catalytic 
cysteine in the cysteine-based PTPs, leading to inhibition of the catalytic activity 
(Ostman, 2011). The involved reactive-oxygen-species (ROS) are often induced by 
surface receptors such as receptor PTKs, integrins or G-protein-coupled receptors, 
leading to temporal inhibition of PTPs counteracting the activated signaling events. 
This mechanism can also play a pathogenic role. For example, the oncogenic kinase 
FLT3-ITD (Fms-like tyrosine kinase 3 with internal tandem duplication) causes elevated 
ROS levels in the leukemic cells, leading to oxidation of PTPs like PTPRJ or PTPN6 
which further enhances the leukemic phenotype (Godfrey, 2012; Jayavelu, 2016). 
Similar to the ligand-binding to other receptors, the extracellular domain of RPTPs 
can also bind ligands. The ligand binding presumably leads to conformational changes 
within the PTP molecules, leading to either activation or inhibition of the phosphatase 
activity. Likewise, the dimerization of RPTPs can also regulate the activity. For PTPRC, 
the forced dimerization can inhibit the activity. However, the functional outcome of 
ligand induced dimerization is strongly dependent on the exact sterical layout of the 
RPTPs. This may be influenced differentially by different ligands or by post-
translational modification of the PTP, so there is no general mechanism predicting 
activation or inhibition by dimerization (den Hertog, 2008).   
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1.2.3 PTPs in health and disease 
PTPs can be dys-regulated in a pathological context. For example, PTP gene 
expression can be altered. Both, down-regulation of some PTPs e. g. by promoter 
methylation, or up-regulation of PTPs in diseases have been reported. In addition to 
epigenetic changes, also mutations (loss-of-function or gain-of-function) in the protein-
coding sequence or in promoter regions and examples for the complete loss of genes 
are known (Ostman, 2006). These abnormalities can lead to hereditary diseases  
(Hendriks, 2013) or play a role in the development of malignancies. Interestingly, PTPs 
can not only appear as tumor suppressors in their role as counteractors of oncogenic 
kinases, but they can also act as oncogenes (Ostman, 2006; Julien, 2011). A well 
characterized example is PTPN11 (SHP-2), which is constitutively activated by 
mutations in some cancer entities, e. g. in 5 -10 % of acute myeloid leukemia (AML) 
patients. PTPN11 also activates the Ras / ERK signaling pathway and thereby 
contributes to cell transformation downstream of several oncogenic tyrosine kinases, 
including BCR-ABL1 (Gu, 2018). This highlights again the importance and differential 
function of PTPs in signaling networks. Therefore, the analysis of PTPs in oncogenic 
contexts may further help in understanding specific phenotypes.  
In this thesis, I mainly focused on PTPN6, PTPRC, and PTPRG for the functional 
analyses, and therefore, some detailed information for these PTPs is provided in the 
following sections. 
 
1.2.4 PTPN6 (SHP-1)  
PTPN6 is a cytoplasmatic phosphatase, 
expressed as 4 different isoforms: 3 of them with 
variations in the N-terminus, and one “long” 
isoform with differences in the C-terminus due to 
alternative splicing resulting in a reading frame 
shift. All of them consist of N-terminal tandem 
SH2 (SRC homology 2) domains and one active 
PTP domain (Figure 1-4). The predominantly hematopoietic isoform is 595 amino acids 
long with the molecular mass of about 68 kDa. In the inactive state, the N-terminal SH2 
(N-SH2) domain folds into the catalytic domain and thereby blocks access of 
substrates to the catalytic-site. An allosteric switch, opening the active-site is caused by 
binding of phosphopeptides to the N-SH2 domain. In addition, the activity of PTPN6 is 
modulated by tyrosine phosphorylation of the C-terminus (Hendriks & Böhmer, 2016).  
Figure 1-4. Domain 
structure of PTPN6. 
PTPN6 consists of two 
SH2 (SRC homology 
2) domains, an active 
PTP domain (PTP) 
and a short C-terminal 
tail.  
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In the hematopoietic compartment, PTPN6 may play a role as a tumor suppressor. 
Loss or reduction of PTPN6 expression, caused by promoter methylation, or allele loss 
is often found in leukemia, lymphoma, and multiple myeloma cases. Naturally occurring 
mouse strains with defects in the Ptpn6 gene e. g. motheaten (no functional PTPN6) 
and motheaten viable (PTPN6 with 80 % reduced activity) have implicated 
hematological functions of PTPN6. Homozygous mice suffer from chronic inflammation 
and autoimmunity before they die at the age of 3 weeks (motheaten) or 6-9 weeks 
(motheaten viable). Heterozygous animals develop leukemia and lymphoma at higher 
age. These findings support the idea of PTPN6 as a tumor suppressor. 
In contrast to that, there are also reports, that PTPN6 may act as an oncogene in 
some epithelial- and ovarian cancer types, where PTPN6 is rather over-expressed than 
down-regulated (Julien, 2011; Hendriks & Böhmer, 2016). 
The PTPN6 mouse models implicate a possible role of PTPN6 in counteracting 
leukemia. Therefore several study groups already addressed the possible influence of 
PTPN6 in CML cell lines and patient samples: PTPN6 is reported to directly interact 
with BCR-ABL1 (Liedtke, 1998; Bruecher-Encke, 2001) and the down-regulation of 
PTPN6 is associated with CML disease progression from CP to AP and BC (Amin, 
2007; Li, 2014). Most likely, this down-regulation is mediated by promoter methylation 
as shown in different publications (Oka, 2002; Li, 2014; Li, 2017). However, Amin et al. 
rather suggest post-transcriptional modifications of PTPN6 to be responsible for the 
decreased expression and not promoter methylation (Amin, 2007).  
As described above (chapter 1.1.5), some CML patients are refractory to TKIs or 
relapse under TKI treatment, without detectable mutations or expression changes in 
BCR-ABL1. PTPN6 is a direct phosphorylation target of BCR-ABL1 (Tauchi, 1997), and 
may negatively regulate BCR-ABL1 and some of its downstream targets (Liedtke, 
1998; Hendriks & Böhmer, 2016). Considering this, the direct impact of PTPN6 on 
imatinib resistance was analyzed by an Italian study group (Esposito, 2011). They 
analyzed bone marrow samples of CP-CML patients, and found the PTPN6 mRNA 
expression decreasing with sub-optimal response and treatment failure, compared to 
optimal responders. One other study reported a lower expression level of PTPN6 
mRNA at diagnosis in a small group of CML patients not responding after 3 months of 
imatinib treatment, but could not show a significant difference (Papadopoulou, 2016).   
Taken together, the currently available literature reports do not yet give a clear 
picture on the influence of the PTPN6 on CML treatment outcome. Therefore, I 
included PTPN6 in the functional analyses of TKI response in this thesis.    
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1.2.5 PTPRC (CD45)  
The receptor-like tyrosine phosphatase 
PTPRC, also known as CD45, is commonly 
expressed on all nucleated cells of the 
hematopoietic system. Expression levels 
generally increase with hematopoietic 
differentiation. It consists of an extracellular 
domain harboring two or three fibronectin-like 3 
sub-domains, a transmembrane domain, and 
two intracellular phosphatase domains. The 
membrane proximal PTP D1 domain is 
catalytically active, whereas the C-terminal PTP 
D2 domain is catalytically inactive (see Figure 
1-5), but appears to be important for the 
phosphatase activity of D1. PTPRC is expressed as different N-terminal splice- and 
glycosylation variants, with molecular masses ranging from 180 to 240 kDa. The 
expression of different PTPRC isoforms can be used to distinguish sub-sets of cells 
and their activation status (Hermiston, 2009).  
The most prominent PTPRC substrates are SFK. These membrane-associated non-
receptor PTKs are key mediators of cellular proliferation, survival, migration, growth 
factor-, and cytokine signaling-pathways, including T- and B-cell antigen receptor 
signaling. The activity of SFKs is tightly regulated. In brief, an inhibitory tyrosine residue 
in the C-terminal tail gets phosphorylated by PTKs (e. g. Csk (C-terminal SRC kinase)), 
and this phospho-tyrosine (pY) binds in an intramolecular fashion to the SH2 domain of 
the SFK, thereby forming an inactive conformation. This inhibitory C-terminal 
phosphorylation (site pY530 in human cSRC) can be de-phosphorylated by PTPs, 
resulting in a “primed”, open conformation allowing auto-phosphorylation of a tyrosine 
residue in the kinase domain (site pY419 in human cSRC referred to as “pSFK” in 
immunoblots later in this thesis), which is needed for full activation of the kinase. 
PTPRC is known to activate SFKs by de-phosphorylation of the C-terminal inhibitory 
pY-site. Despite this activating role of PTPRC, there are also reports that PTPRC can 
regulate the phosphorylation of the SFK active-site tyrosine, resulting in a negative 
regulation of SFK activity, thereby providing a negative feedback mechanism 
(Hermiston, 2009; Rhee & Veillette, 2012). This regulatory role has been elaborately 
investigated for p56 (Lck), a prominent SFK in T-lymphocytes (McNeill, 2007).  
Homozygous loss, or the expression of mutated PTPRC resulting in differentiation 
defects of lymphocytes, lead to a SCID (severe combined immunodeficiency) 
Figure 1-5. PTPRC 
domain structure. The 
C-terminal PTP 
domains are located in 
the cytoplasm of the 
cell. FN: fibronectin-
like 3 domain, PTP D1: 
active phosphatase 
domain, PTP D2: 
inactive phosphatase 
domain.  
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phenotype in mice and humans, caused by a lack of peripheral T-lymphocytes (Cale, 
1997; Kung, 2000; Tchilian, 2001). Polymorphisms of splicing-related bases in the 
PTPRC gene that change the expression pattern of the splice variants are linked to 
increased incidences of e. g. multiple sclerosis, autoimmune hepatitis, systemic 
sclerosis, and HIV (human immunodeficiency virus) infections, or are associated with a 
protective effect against hepatitis B infection (Hermiston, 2009).  
Similar to the dual role that PTPRC can play in SFK activation, it can neither be 
clearly labeled as a tumor suppressor, nor as an oncogene related to leukemia 
development. PTPRC was reported to have tumor suppressive functions (Porcu, 2012), 
while others reported leukemia-promoting features (Kumar, 2016; Saint-Paul, 2016), or 
found low PTPRC expression correlated with increased treatment-free survival in CLL 
(chronic lymphocytic leukemia) (Rizzo, 2013).  
Obviously, the role of PTPRC is cell-type dependent, but up to date, no reports 
addressing the role of PTPRC in CML patients or CML cell lines are published. This 
and the finding that PTPRC expression was correlated with treatment outcome in the 
study presented in this thesis (chapter 5.1) made PTPRC an interesting PTP to be 
followed up in more detail.   
 
1.2.6 PTPRG (RPTPgamma) 
PTPRG is a receptor-like classical PTP with an extracellular domain harboring a 
carbonic anhydrase-like (CA) and a fibronectin-like 3 (FN) sub-domain, a 
transmembrane domain, and an intracellular catalytically active D1- and a catalytically 
inactive D2-phosphatase domain (Figure 1-6), similar to PTPRC. PTPRG was reported 
having tumor suppressor functions in a variety of tissues. As reviewed by Stoker, there 
are reports on inactivating mutations, LOH (loss of heterozygosity), and promoter 
methylation of the PTPRG gene (Stoker, 2016). In Merkel-cell carcinoma (an 
aggressive rare skin cancer), nasopharyngeal carcinoma, as well as in ovary, lung, and 
renal tumor samples, a PTPRG down-regulation, gene disruption, or silencing were 
found. In gastric carcinoma studies, lymph-node metastases revealed a significantly 
higher rate of PTPRG silencing by promoter methylation than the primary tumors. 
Studies about nasopharyngeal carcinoma (Cheung, 2008) and breast cancer (Liu, 
2004; Shu, 2010) provided experimental evidence that PTPRG negatively influences 
proliferation and anchorage-independent growth. In a study analyzing childhood ALL 
(Xiao, 2014), PTPRG was found down-regulated by promoter methylation, especially in 
samples with mutated Ras gene. The authors found PTPRG to counteract Ras 
signaling by de-phosphorylation of ERK, a downstream Ras target. In contrast to all 
these findings, PTPRG was found up-regulated in immunohistochemistry of frozen or 
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paraffin-embedded tissues of high-grade 
astrocytomas and subtypes of lymphomas 
(Vezzalini, 2007). However, this study 
completely lacks functional analyses, 
leaving the suspected tumor-promoting 
abilities of PTPRG unproven.   
Of special interest for this thesis were 
reports addressing PTPRG in CML cell 
lines or patients. Two reports of the Italian 
working group headed by Claudio Sorio 
are published (Della Peruta, 2010; 
Vezzalini, 2017). They found PTPRG 
down-regulated in CML patient blood and 
bone marrow samples, and described a 
higher PTPRG level after imatinib 
treatment in patients responding to the 
therapy, but not in non-responding 
patients. In functional analyses, they found a direct interaction of PTPRG with BCR-
ABL1, and showed that expression of PTPRG in K562 cells could diminish colony 
formation in methylcellulose, and decreased tumor size in xenografted nude mice. 
In my patient analyses, I found a positive correlation of PTPRG mRNA expression 
levels before CML treatment with favorable treatment outcome after 9 months of 
nilotinib treatment (chapter 5.1). Taken together with the described tumor suppressor 
functions, I aimed to answer the question, whether PTPRG has a direct impact on the 
TKI treatment response and might therefore suit as a prognostic marker of CML 
treatment outcome.  
Figure 1-6. PTPRG domain 
structure. PTPRG consists of 
an extracellular N-terminal 
carbonic anhydrase like (CA) 
domain, a fibronectin-like 3 
(FN) domain, a 
transmenbrane domain, and 
two intracellular PTP 
domains, one (D1) with 
phosphatase activity, the 
membrane distal domain 
(D2) lacking catalytic 
activitiy.  
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2 Aim of the Study 
The first aim of the study was to assess the potential influence of the PTP-status of 
CML patients for treatment response to the second-generation TKI nilotinib, and to 
identify PTPs that may be associated with the treatment response. To this end, a qPCR 
platform to analyze the mRNA expression level of 38 selected PTPs in primary CML 
patient samples should be set up and the PTP mRNA expression levels at timepoint of 
diagnosis should be correlated to the patient’s individual nilotinib treatment response.   
In the second part of the thesis, cell line models were to be established with 
manipulated expression levels of the candidate PTPs by either shRNA-mediated 
knockdown, CRISPR/Cas9-mediated knockout, or exogenous over-expression as 
applicable. These cell line models should then be used to study the direct influence of 
either PTP on the treatment response, by directly assessing the sensitivity to nilotinib, 
imatinib, and dasatinib treatment. 
The third part of the thesis studies should focus on investigating mechanisms that 
cause the changed sensitivity to TKI, by analyses of selected signaling pathways. 
Using this information, new possible treatment options or reasonable combination-
treatments should be identified.  
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3 Material 
3.1 QPCR primers for PTP and control genes  
Oligos were purchased from Sigma-Aldrich. 
Gene 
name 
Common 
name 
Primer forward Primer reverse Size 
PTPN1 PTP1B CGTTAAAATGCGCACAATAC GCTGTCGCACTGTATAATATG 120 bp 
PTPN2 TC-PTP GGCACCTTCTCTCTGGTAGA TCTCAGTTGATCTGGGGTCT 129 bp 
PTPN4 PTPMEG1 TACGATCAGTCAGAGAACTTG GGAGATAAGCCTATGTGTTG 119 bp 
PTPN6 SHP-1 CAAGAACATTCTCCCCTTTG TCTTGATGTAGTTGGCATTG 98 bp 
PTPN7 LC-PTP AGGAGAAATGTGTCCACTAC AAAGAGGATGTGCTTTACTG 155 bp 
PTPN9 PTPMEG2 AGAAACTCGAAGGAAGGAAG GATGGTGAATTTTCCACTGAG 88 bp 
PTPN11 SHP2 CCTGAATTTGAAACCAAGTG ACATTTACTCTTTCCTCTCTCC 168 bp 
PTPN12 PTP-PEST ATGAATCTCGTAGGCTGTATC CCTCATTAAGCTTATCATGTCC 101 bp 
PTPN13 
FAP1, PTP-
BAS 
GAAGAACCAGTTCGAAGATAC ACTTAAGGTTTCATCTACCCC 171 bp 
PTPN14 PTP PEZ CAGAATTGGAAGACAAGCGG TAAAACTTGTGTCGTGTGGC 177 bp 
PTPN18 PTP-HSCF AGGAGAAGTGGCTGAATGAG GTAGCTGGTACACAGAACGG 84 bp 
PTPN21 PTPD1 ATTTAGGTGGCATGACATTG CAACACAGAGTCTCCAAATG 137 bp 
PTPN22 Lyp GTGAAACTCGAACTATCTACC TCTTGGTAACAACGTACATC 112 bp 
PTPN23 HD-PTP CTTTGAGGGCTGTAGTGTC CGCTCCAAGGTTGTAGAGAA 187 bp 
PTPRA RPTPα CAACAATGCTACCACAGT AAGAGAAGTTAGTGAAGAAGTT 121 bp 
PTPRB VE-PTP CTCTGTGGACATTTATGGAG ACTGGATCTCTGTGATACTC 195 bp 
PTPRC CD45 CATATGACTATAACAGAGTGCC ATGTATTTGCTTGGTTCCTC 118 bp 
PTPRE RPTPε ATGACCATTCTAGGGTGATTC CCATCTATGTAGGAAGCATTG 79 bp 
PTPRG RPTPγ GACGAGAAGGAGAAGACGTT AACAGGTAAAGGCTATCGGG 89 bp 
PTPRJ DEP-1 ATAGGCAATGAGACTTGGGG CATGGCTTCCAATGCTTTCA 172 bp 
PTPRK RPTPκ CTTGAAACTGATACTTCAGGTG TTAGGCAGTGGATAATCGTC 80 bp 
PTPRM RPTPµ GGCCAGATGACACAGAGATA CATGCACACCTCTCTTTTCAA 111 bp 
PTPRO GLEPP1 ATTGAAAATCTGGTTCCTGG ACAATAGCAAATGTCACAGG 101 bp 
PTPRS RPTPσ CAGAGGATGAGTACCAGTTC CTTTAGGTTGCATAGTGGTC 76 bp 
PTPRT RPTPρ AGAGGAGCAATATGTGTTTG GATATTGTAGTAGAGAGAACGG 103 bp 
PTPRZ1 RPTPζ TGAGGTGCTGGACAGTCATA GCTCAGGAGCTGGAATTGTT 100 bp 
DUSP1 MKP1 ACTACCAGTACAAGAGCATC GATTAGTCCTCATAAGGTAAGC 183 bp 
DUSP2 PAC1 CAACTTCAGTTTCATGGGG CTGAAACTCTGAGGAGGTAG 184 bp 
DUSP3 VHR TTGGCTCAAAAGAATGGC ATCATGAGGTAGGCGATAAC 86 bp 
DUSP4 MKP2 TATCAGTACAAGTGCATCCC ATCGATGTACTCTATGGCTTC 84 bp 
DUSP6 MKP3 TGGTGTCTTGGTACATTGCT CGTTCATCGACAGATTGAGC 92 bp 
PTP4A1 PRL1 ACGAAGATGCAGTACAATTC TCAAGTTCCACTTCCAGTAG 183 bp 
PTP4A2 PRL2 TACGTTGCACATTTATGGCG GCTCACTTGTCAGCGAAAAT 82 bp 
PTP4A3 PRL3 AGCACCTTCATTGAGGAC GCGTTTTGTCATAGGTCAC 79 bp 
PTEN TEP1 GGCTAAGTGAAGATGACAATC GTTACTCCCTTTTTGTCTCTG 169 bp 
ACP1 LMW-PTP CTGTTTGTGTGTCTGGGTAAC TGATCGGTTACAAGTTTCCTG 74 bp 
CDC25A  AGAAGAATACATTCCCTACCTC CAAGAGAATCAGAATGGCTC 76 bp 
CDC25B  ATTGTAGACTGCAGATACCC GAAAATGAGGATGACTCTCTTG 147 bp 
GUSB  TAGAGCAGTACCATCTGGGT GCTGCACTTTTTGGTTGTCT 160 bp 
B2M  TACACTGAATTCACCCCCAC GATGCTGCTTACATGTCTCG 110 bp 
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3.2 The shRNA sequences for PTP knockdown 
Target 
Gene 
Ordering number 
(Sigma-Aldrich) 
Inserted shRNA sequence into pLKO.1 vector 
Control SHC002 
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTG
CTCTTCATCTTGTTGTTTTT 
ACP1 
TRCN0000002598  
CCGGCTATGTATGGATGAAAGCAATCTCGAGATTGCTT
TCATCCATACATAGTTTTT 
TRCN0000002599 
CCGGGCCCATAAAGCAAGACAGATTCTCGAGAATCTGT
CTTGCTTTATGGGCTTTTT 
TRCN0000002600  
CCGGGAACTACTTGGGAGCTATGATCTCGAGATCATAG
CTCCCAAGTAGTTCTTTTT 
DUSP1 
TRCN0000002514 
CCGGAGTTTGTGAAGCAGAGGCGAACTCGAGTTCGCC
TCTGCTTCACAAACTTTTTT 
TRCN0000002516 
CCGGGCTCTGTCAACGTGCGCTTCACTCGAGTGAAGC
GCACGTTGACAGAGCTTTTT 
TRCN0000002518 
CCGGCTGCCGCTCCTTCTTCGCTTTCTCGAGAAAGCGA
AGAAGGAGCGGCAGTTTTT 
PTP4A2 
TRCN0000002924 
CCGGCTTCAGAGATACCAATGGGCACTCGAGTGCCCA
TTGGTATCTCTGAAGTTTTT 
TRCN0000002926 
CCGGATACCGACCTAAGATGCGATTCTCGAGAATCGCA
TCTTAGGTCGGTATTTTTT 
TRCN0000002927 
CCGGCAGATAGTAGATGATTGGTTACTCGAGTAACCAA
TCATCTACTATCTGTTTTT 
PTPN6 
TRCN0000006885 
CCGGCCCAGTTCATTGAAACCACTACTCGAGTAGTGGT
TTCAATGAACTGGGTTTTT 
TRCN0000006886 
CCGGGCATGACACAACCGAATACAACTCGAGTTGTATT
CGGTTGTGTCATGCTTTTT 
TRCN0000011052 
CCGGCCTCTCCCTGACCCTGTATATCTCGAGATATACA
GGGTCAGGGAGAGGTTTTT 
PTPN12 
TRCN0000002830 
CCGGCAGCCGAGTTAAATTGACATTCTCGAGAATGTCA
ATTTAACTCGGCTGTTTTT 
TRCN0000002831 
CCGGCCACCAGAAGAATCCCAGAATCTCGAGATTCTG
GGATTCTTCTGGTGGTTTTT 
TRCN0000002832 
CCGGGCTTTGCAGGTTATCAGAGATCTCGAGATCTCTG
ATAACCTGCAAAGCTTTTT 
PTPRC 
TRCN0000002845 
CCGGGCTGCACATCAAGGAGTAATTCTCGAGAATTACT
CCTTGATGTGCAGCTTTTT 
TRCN0000002847 
CCGGCCTTTCCTACAGACCCAGTTTCTCGAGAAACTGG
GTCTGTAGGAAAGGTTTTT 
TRCN0000002848 
CCGGGCAGGGTCAAACTACATAAATCTCGAGATTTATG
TAGTTTGACCCTGCTTTTT 
PTPRE 
TRCN0000002893 
CCGGCCGAGTGATCCTTTCCATGAACTCGAGTTCATGG
AAAGGATCACTCGGTTTTT 
TRCN0000002894 
CCGGGCTACCGACAGAAGGACTATTCTCGAGAATAGT
CCTTCTGTCGGTAGCTTTTT 
TRCN0000002896 
CCGGTGGACACATACAAGGAACTTTCTCGAGAAAGTTC
CTTGTATGTGTCCATTTTT 
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3.3 Buffer list 
RIPA lysis buffer 1 % NP-40  
1 mM EDTA  
50 mM Tris-HCl pH 7.4  
150 mM NaCl  
0.25 % Sodium-deoxycholate  
Add fresh: “PhosSTOP” tablet and “cOmplete” tablet 
diluted in RIPA according to manual 
10x TBST pH 7.6 200 mM Tris 
1.37 M NaCl 
10 ml Tween 20 
Adjust pH to 7.6 with HCl, then add Tween 20. 
PBS pH 7.4 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
2 mM KH2PO4 
Adjust pH 7.4 with HCl 
Stripping buffer 100 mM 2-mercaptoethanol 
2 % SDS 
62,5 mM Tris-HCl pH 6.7 
6x Sample loading buffer 375 mM Tris-HCl pH 6.8 
12 % SDS 
30 % Glycerol 
500 mM DTT 
Spatula tip Bromphenol blue 
4x Separation gel buffer pH 8.8 1.5 M Tris-HCl pH 8.8  
0.4 % SDS  
4x Stacking gel buffer pH 6.8 0.5 M Tris-HCl pH 6.8 
0.4 % SDS  
10x SDS running buffer 250 mM Tris 
2 M Glycine 
1% SDS 
1x Tank blot transfer buffer 25 mM Tris 
192 mM Glycine 
20 % Methanol 
PEI Dissolve PEI (10 µg/µl) in water and adjust pH to 7.2 
with HCl. Sterilize by filtration, store at 4 °C.   
10x Erythrocyte lysis buffer 1.55 M KH4Cl 
100 mM KHCO3 
1.22 mM EDTA 
PE-buffer Add 2 mM EDTA to 1x PBS 
 
3.4 Composition of polyacrylamide gels 
   
Stacking gel Separation gel 
5 % 10 % 15 % 
Water 3.43 ml 4.1 ml 2.4 ml 
Acrylamide 1 ml 3.3 ml 5 ml 
4x Stacking gel buffer pH 6.8 1.5 ml - - 
4x Separation gel buffer pH 8.8 - 2.5 ml 2.5 ml 
10 % APS (in water) 60 µl 100 µl 100 µl 
TEMED 6 µl 8 µl 8 µl 
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3.5 Immunoblotting antibodies 
Protein MW Cat. no Species 
Dilution prim. 
antibody  
(in 1x TBST) 
Blocking/ sec. 
antibody  
(in 1x TBST) 
Sigma-Aldrich 
Actin 42 kDa A5441 mouse 1:5 000 5 % BSA 5 % dry milk 
Santa Cruz Biotechnology 
Bcl-2 26 kDa sc-7382 mouse 1:250 5 % BSA 5 % dry milk 
cSRC 60 kDa sc-18 rabbit 1:1 000 5 % BSA 5 % dry milk 
Lyn 53/56 kDa sc-7274 mouse 1:1 000 5 % BSA 5 % dry milk 
p27 27 kDa sc-528 rabbit 1:1 000 5 % BSA 5 % dry milk 
p27 27 kDa sc-1641 mouse 1:250 5 % BSA 5 % dry milk 
STAT5 90 kDa sc-835 rabbit 1:1 000 5 % BSA 5 % dry milk 
PTPN6 68 kDa sc-287 rabbit 1:1 000 5 % BSA 5 % dry milk 
PTPRC 155 kDa sc-25590 rabbit 1:500 5 % dry milk 5 % dry milk 
Cell Signaling Technology 
BCR-ABL1 
135 kDa c-
ABL1 210 kDa 
BCR-ABL1 
# 2862 rabbit 1:1 000 5 % BSA 5 % dry milk 
pBCR-
ABL1 
135 kDa c-
ABL1 210 kDa 
BCR-ABL1 
# 2861 rabbit 1:1 000 5 % BSA 5 % dry milk 
pSFK ~50-60 kDa # 6943 rabbit 1:1 000 5 % BSA 5 % dry milk 
ERK 42/44 kDa # 9107 mouse 1:1 000 5 % BSA 5 % dry milk 
pERK 1/2 42/44 kDa # 9106 mouse 1:1 000 5 % BSA 5 % dry milk 
AKT 60 kDa # 9272 rabbit 1:1 000 5 % BSA 5 % dry milk 
pAkt 60 kDa # 9271 rabbit 1:1 000 5 % BSA 5 % dry milk 
BD Biosciences 
pSTAT5 90 kDa BD611964 mouse 1:1 000 5 % BSA 5 % dry milk 
Biozol 
Vinculin 124 kDa BZL03106 mouse 1:1 000 5 % BSA 5 % dry milk 
Custom made 
PTPRG ~160 kDa 
Della 
Peruta 
(2010) 
rabbit 1:1 000 1 % BSA 1% BSA 
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3.6 Reagents, media, enzymes, and drugs 
Product Company 
Ordering 
number 
Acrylamide Rotiphorese Gel 30 (37,5:1) Fa. Roth 3029.1 
Blasticidin  
Life 
Technologies 
R21001 
CellTiter-Blue reagent Promega G8081 
cOmplete tablet Protease inhibitor cocktail Roche 04693132001 
Dasatinib  Selleckchem S1021 
DMEM-F12 
Dulbecco's Modified Eagle 
Medium: Nutrient Mixture F-
12 
Gibco 21041-025 
ECL Western Lightning Plus-ECL Perkin Elmer 0RT2655 
FCS Fetal calf serum Sigma-Aldrich F7524 
IBM Iscove Basal Medium Biochrom FG0465 
Idelalisib CAL-101 Selleckchem S2226 
Imatinib Obtained from Siavosh Mahboobi, University of Regensburg 
Iodonitrotetrazolium chloride Sigma-Aldrich I8377 
Methylcellulose  3 % stock solution R&D Systems HSC001 
Nilotinib  Selleckchem S1033 
Opti-MEM Reduced Serum Medium Gibco 31985-047 
P/S Penicillin/streptomycin Sigma-Aldrich P0781 
PEI Polyethylenimine (branched) Sigma-Aldrich 408727 
PeqGOLD Trifast  VWR Peqlab 30-2010 
PhosSTOP tablet 
Phosphatase inhibitor 
cocktail 
Roche 04906845001 
Polybrene Hexadimethrine bromide Sigma-Aldrich H9268 
Puromycin Stock 2 mg/ml in water Sigma-Aldrich P8833 
Restriction 
enzymes 
AvrII, BamHI-HF,  
BglII, BsmBI,  
EcoRI, MfeI-HF,  
SalI, PvuI, 
XbaI, XhoI 
NEB 
R0174, R3136, 
R0144, R0580, 
R0101, R3589 
R0138, R0150 
R0145, R0146 
RPMI-1640 
Roswell Park Memorial 
Institute - medium 
Sigma-Aldrich R8758 
TEMED 
N,N,N',N'-Tetramethyl-
ethylenediamine 
SERVA 35930.02 
Trypsin-EDTA 
(0.05%) 
Ready to use Gibco 25300054 
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3.7 Plastic ware and kits 
Product Company 
Ordering 
number 
1 ml syringes Inject-F Braun 9166017V 
10 ml syringes Inject Braun  4606108V 
Amicon Ultra tube 
Amicon Ultra-15 
Ultracel – 30K 
Merck Millipore UFC903024 
Black 96-well plates with clear bottom Greiner 655090 
First strand cDNA synthesis kit ThermoFisher Scientific #K1612 
Maxima SYBR Green/ROX qPCR Master Mix 
(2x) 
ThermoFisher Scientific #K0223 
Nitrocellulose 
membrane 
pore size 0.2µm Biostep 01-14-101 
qPCR plates  Sarstedt 72.1982.202 
qPCR sealing foils  Sarstedt 95.1999 
qPCR set Contains plates & foils Roche 04729692001 
QuikChange XL Site-Directed Mutagenesis Kit Agilent Technologies 200517 
Syringe filter units Filtropur S 0.2µm Sarstedt 83.1826.001 
Zymoclean Gel DNA recovery Kit Zymoresearch D4002 
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4 Methods 
4.1 Patient studies 
The cDNA samples and the corresponding BCR-ABL1IS values of 66 patients 
participating in the TIGER (Tasigna / Interferon in Germany) study (NCT01657604) 
were kindly provided by Prof. Dr. Andreas Hochhaus and PD Dr. Thomas Ernst, Jena. 
The cDNA preparation and BCR-ABL1IS determination was described in our joint 
publication (Drube, 2018). The prepared cDNA was then analyzed in this thesis for the 
mRNA expression pattern of 38 selected PTP genes (chapter 3.1) as described in 
chapter 4.4. All 66 patients were grouped according to whether or not they had a MR4 
or better (BCR-ABL1IS ≤ 0.01 %) after 9 months of nilotinib study treatment. The mRNA 
levels of each PTP before study-treatment start was then compared between those two 
groups. Since the TIGER study protocol allowed some pretreatments, two sub-cohorts 
of patients were analyzed. For details see chapter 5.1.  
 
4.2 Leukocyte cDNA of healthy donors 
All donors have given written consent, and the analysis was approved by the local 
ethics committee (vote 4461-06/15). Primary leukocytes of healthy donors were 
isolated from 10 ml fresh blood sample by erythrocyte lysis. In brief, 40 ml of 
1 x erythrocyte lysis buffer were added to the blood in a 50 ml tube and incubated on 
ice for 10 min. The mixture was inverted several times during the incubation. The cells 
were centrifuged at 400 g, 4°C, for 10 minutes. The supernatant was discarded, and 
the cells were again resuspended in 1 x erythrocyte lysis buffer, incubated for 
10 minutes on ice and centrifuged as described before. The supernatant was 
discarded, and the cells were washed with 25 ml PE-buffer and centrifuged at 400 g, 
4°C, for 5 minutes. Total RNA was isolated using 2 ml of PeqGOLD TriFast solution 
according to the manual of the manufacturer and cDNA was transcribed from 5 µg of 
total RNA with the First strand cDNA synthesis kit using random hexamer primers 
according to the protocol of the manufacturer. QPCR was performed as described in 
chapter 4.4.  
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4.3 RNA isolation and cDNA preparation of cell lines 
Two million cells were centrifuged (500 g, 5 min), and the supernatant was 
discarded. Without washing, 1 ml of PeqGOLD TriFast solution was added, and the 
RNA was isolated according to the protocol of the manufacturer. The cDNA was 
transcribed from 5 µg of total RNA with the First strand cDNA synthesis kit using 
random hexamer primers according to the protocol of the manufacturer. QPCR was 
performed as described in chapter 4.4.  
 
4.4   QPCR 
QPCR primers for the 38 PTPs and the control genes (chapter 3.1) were designed 
using the NCBI primer-BLAST tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
Care was taken to pick up all relevant transcript variants of each PTP with equally long 
PCR products in order to get a comprehensive coverage of isoforms for each PTP. 
PCR products were validated for correct size by agarose gel electrophoresis and for 
correct sequence by DNA sequencing (data not shown). The reverse transcribed cDNA 
was diluted to 480 µl with water. Primer stock solutions, containing 1.2 µM of 
respective forward and reverse primers were prepared and 5 µl were transferred to 
each well of the 96-well qPCR plate. A master mix containing 10 µl of 2 x Maxima 
SYBR Green/ROX qPCR Master Mix and 5 µl of the diluted cDNA per sample was 
added to the pre-set primers. The plate was sealed with the provided foil and carefully 
mixed by vortexing. After a short spin, the qPCRs were carried out in a Roche 
LightCycler480 system with an initial denaturation step of 10 min, 95°C, and 40 cycles 
with 15 sec, 95 °C; 30 sec, 55 °C; and 30 sec, 72 °C, followed by a melting curve 
analysis. Beta-glucuronidase (GUSB) and Beta-2 microglobulin (B2M) were used as 
control genes. Each PTP and housekeeping gene was analyzed in duplicates, relative 
mRNA expression was calculated as 2-ΔCT using the mean CT value of GUSB and 
B2M.  
 
4.5 Statistical analyses  
4.5.1 Statistical analysis of patient data 
The statistical analysis of patient data was done by PD Dr. Markus Pfirrmann, 
Munich and colleagues. The following method description was provided by PD Dr. 
Markus Pfirrmann (Drube, 2018): To identify the prognostic influence of the candidate 
variables on achieving BCR-ABL1IS ≤ 0.01 % (MR4) status at 9 months (yes or no), 
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univariate logistic regression analyses were performed (Hosmer & Lemeshow, 1989). 
Significance was judged using the likelihood ratio test. Since the study has an 
exploratory character, multiplicity was not considered. For the two-sided P values, the 
unadjusted significance level was 0.05. All calculations were performed with the SAS 
software version 9.4 (SAS Institute, Cary, NC, USA).  
 
4.5.2 Statistical analysis of in vitro experiments 
For the in vitro experiments the Wilcoxon matched-pairs test was employed using 
GraphPad Prism 5. Note that comparison of 6 independent values is the minimum 
sample number for this test. This precluded analyses of data sets with less than 
6 independent experiments. 
 
4.6 Cell lines 
K562 and KCL-22 were purchased from the German Collection of Microorganisms 
and Cell Cultures (DSMZ, Braunschweig, Germany). Cells were cultured in RPMI-1640 
supplemented with 1 % penicillin/streptomycin (P/S), and 10 % heat-inactivated fetal 
calf serum (FCS). HEK293T cells were purchased from the DSMZ, and cultivated with 
DMEM-F12 medium, supplemented with 10 % FCS and 1 % P/S. During transfection, 
HEK293T cells were cultivated without P/S (see chapter 4.8).  
 
4.7 The shRNA-mediated knockdown of PTPs 
In order to down-regulate the gene expression level of selected PTPs, we decided to 
use the technique of RNA interference (RNAi). RNAi selectively decreases the mRNA 
level of the target proteins, leading to a decreased expression of the protein itself. All 
this is mediated by the presence of short double-stranded RNA (dsRNA) molecules, 
complementary to the target sequence. In order to exogenously introduce this dsRNA, 
e. g. synthetic small (less than 30 bp) double stranded siRNA (small interfering RNA) 
can directly be transfected into the cells. In the cells, the siRNA assembles with RISC 
(RNAi –induced silencing complex). RISC unwinds the dsRNA and binds one strand of 
the siRNA molecule, which is the template to bind the complementary mRNA strand. 
This strand gets cleaved by the endonuclease activity of RISC, leading to mRNA 
degradation. 
This siRNA approach is only transient. In order to get a stable down-regulation, the 
dsRNA needs to be continuously expressed in the cell. This can be achieved by the 
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transfection of cells with plasmids encoding shRNAs (small hairpin RNAs). These 
RNAs are designed to fold to a dsRNA strand with a linking single stranded hairpin. 
These molecules are processed by the RNase Dicer that cleaves off the hairpin 
structure to form siRNAs and enter the pathway described above. 
In our study, we used the pLKO.1 system of Sigma-Aldrich. It uses Lentiviral-
mediated transduction of the shRNA encoding sequence to the CML cell lines. The 
target sequences are outlined in chapter 3.2. Transduction of target cells was carried 
out as described in chapter 4.8. The cells were selected using puromycin (2 µg/ml) for 
5 days. After that, cells were analyzed for remaining mRNA expression of the target 
gene.  
 
4.8 Viral transduction 
1.5 million HEK293T cells were seeded in DMEM-F12 medium supplemented with 
10 % FCS and 1 % P/S in a 10 cm cell culture dish.  16 hours later, the medium was 
replaced by DMEM-F12 with 10 % FCS, but without P/S, and the HEK293T cells were 
transfected using PEI reagent: For production of lentiviral particles, 10 µg pMDL, 5 µg 
pRSV, 2 µg VSVg (packaging plasmids were originally obtained from Dr. Carol 
Stocking, HPI, Hamburg, Germany) and 10 µg of the lentiviral vector were added to 
0.5 ml of OptiMem medium, and to a second tube, 6.75 µl PEI stock (10 µg/µl) were 
added to 0.5 ml OptiMem. Then the 0.5 ml of PEI solution were added to the first tube, 
and mixed thoroughly by pipetting up and down several times. After an incubation 
period of 20 minutes at room temperature, the PEI / DNA mixture was added dropwise 
onto the HEK293T cells. For production of retroviral particles, 10 µg RV GagPol, 2 µg 
VSVg (packaging plasmids were originally obtained from Dr. Carol Stocking, HPI, 
Hamburg, Germany), 5 µg of retroviral vector, and 4.25 µl of PEI stock (10 µg/µl) were 
used. Six hours after adding the transfection mix to the cells, the supernatant of the 
HEK293T cells was carefully taken off, and was replaced by 10 ml of full DMEM-F12 
containing P/S.  
24 h after start of transfection, the virus containing supernatant of the HEK293T 
cells was transferred to an Amicon Ultra tube using a 10 ml syringe and a 0.2 µm 
syringe filter unit to remove any HEK293T cells. The viral supernatant was centrifuged 
for 15 minutes at 4 000 g. The HEK293T were again cultivated with 10 ml of fresh 
culture medium containing FCS and P/S for 24 h.  
50 000 target cells were seeded in 2 ml of their respective growth medium in 6-well 
cell culture dishes, containing 22 µl of 0.8 µg/µl polybrene (Hexadimethrine bromide) 
solution. The concentrated virus was added dropwise to the target cells, and the culture 
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plate was centrifuged at 500 g for 1 hour. After the centrifugation, the cells were 
incubated at 37°C, 5 % CO2 until the next infection. In total, 3 rounds of infections 
(24 h, 48 h, and 72 h after start of transfection) were carried out. 24 h after the last 
infection, the target cells were washed with their respective growth medium.      
    
4.9 Expression constructs 
4.9.1 PTPN6    
The human PTPN6-WT expression construct was originally obtained from Dr. Axel 
Ullrich (Max-Planck Institute of Biochemistry, Martinsried, Germany). The phosphatase-
dead PTPN6-C453S mutant was generated by Annette Böhmer.  
The two PTPN6 coding sequences (WT and CS) were amplified using the following 
primers: GCA GAA TTC ACG ATG GTG AGG TGG TTT CAC C, and GCA CTC GAG 
GCT TCA CTT CCT CTT GAG G. After gel extraction with the Zymoclean DNA 
recovery kit, the fragments were inserted into the pMSCV-IRES-mCherry (gift from 
Dario Vignali, Addgene # 52114) vector using EcoRI and XhoI restriction enzymes. The 
resulting plasmids (8 083 bp) were analyzed by control digest and sequencing (not 
shown).  
 
4.9.2 PTPRG 
A lentiviral human PTPRG-WT expression construct (coding sequence from 
NM_002841.3) containing a mCherry/Blasticidin expression cassette (pLV-PTPRG-
WT-mCherry/Bsd) was custom made by Vector builder (Cyagen Biosciences Inc., 
Santa Clara, CA, USA). The encoded sequence corresponds to the 1445 aa long splice 
version of PTPRG (Ensembl ENST00000474889.5).  The expression efficiency was not 
very high using this lentiviral system, and the sorting for mCherry expression also did 
not result in high expression levels, since this construct expresses mCherry 
independently of the insert, and therefore, the fluorescence signal does not directly 
reflect the expression of PTPRG. The direct sorting for PTPRG expression was not 
possible, since there are no reliable FACS antibodies commercially available. To 
overcome this, we decided to switch to the retroviral system pMSCV-IRES-mCherry. In 
this system, mCherry and the inserted protein are translated from the identical mRNA 
strand. The vector pLV-PTPRG-WT-mCherry/Bsd was cut with BglII, EcoRI, and AvrII 
in NEB buffer 3.1, and the resulting 5 013 bp fragment with the coding PTPRG-WT 
sequence was isolated and ligated into the BamHI-HF and MfeI-HF cut MSCV-IRES-
mCherry vector (NEB cut smart buffer, 6 313 bp). The final MSCV-PTPRG-WT-IRES-
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mCherry vector (11 326 bp) was analyzed by control digestion and sequencing. In 
order to study the influence of the phosphatase activity itself, we mutated the PTPRG-
WT construct to the phosphatase-dead PTPRG-C1060S (CS) mutant. In this construct, 
the catalytically active cysteine in the membrane proximal PTP domain (PTP D1) is 
replaced by a serine, leading to a catalytically inactive enzyme. The site directed 
mutagenesis resulting in this amino acid change was carried out using the QuikChange 
XL Site-Directed Mutagenesis Kit according to instructions of the manufacturer with the 
following primers: CTG TGT TGG TGC ACT CCA GTG CTG GTG TGG and CCA CAC 
CAG CAC TGG AGT GCA CCA ACA CAG (the mutated base underlined). 
Viral transduction of K562 cells with pMSCV-PTPRG-WT-IRES-mCherry, pMSCV-
PTPRG-CS-IRES-mCherry, or respective empty vector pMSCV-IRES-mCherry was 
done as described in chaper 4.8. Since the vector does not encode any selection 
marker, the cells were sorted for equally high mCherry expression by the colleagues of 
the CF Flow Cytometry of the Fritz-Lipmann-Institute (FLI) Jena. 
 
4.9.3 PTPRC 
The PTPRC expression construct was obtained from Dr. Reiner Lammers 
(University Hospital Tübingen, Germany). It encodes the PTPRC isoform 2 
(NP_563578.2). The coding sequence was subcloned into the lentiviral expression 
vector pLV-MCS-mCherry/Bsd (Vector Builder, Cyagen Biosciences Inc., Santa Clara, 
CA, USA). 
Therefore, the PTPRC vector was cut with SalI, AvrII, and PvuI in NEB Buffer 3.1, 
the 4 620 bp fragment was isolated, and ligated into the gel extracted (Zymogen Gel 
DNA recovery kit, according to manual of the manufacturer) pLV-MCS-mCherry/Bsd 
vector fragment cut with SalI and XbaI (NEB Buffer 3.1). The identity of the resulting 
vector was confirmed by control digestion and DNA sequencing (not shown).  
This expression vector was used to rescue the phenotype of K562 PTPRC knockout 
cell clone A. Therefore, the PTPRC-KO cells were infected with freshly produced viral 
particles made with pLV-PTPRC-mCherry/Bsd or corresponding empty vector (pLV-
MCS-mCherry/Bsd) (chapter 4.8), selected with blasticidin (7.5 µg/µl for 10 days) and 
subsequently sorted for PTPRC expression (PTPRC expression construct) or mCherry 
expression (empty vector) respectively (CF Flow Cytometry of the Fritz-Lipmann-
Institute (FLI) Jena). 
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4.10  CRISPR/Cas 9 
The CRISPR/Cas (Clustered regularly interspaced short palindromic 
repeats/CRISPR-associated protein) system was originally discovered in bacteria and 
archaea, as an acquired immune defense system against viruses and phages: Upon 
infection with foreign DNA (e. g. phage DNA), this DNA is cleaved by the Cas nuclease 
and the resulting small pieces get incorporated into the bacteria or archaea genome 
itself. These pieces are transcribed to crRNA (CRISPR RNA) and serve as guiding 
sequences in case of re-infection: the Cas nuclease is guided to the invading DNA by 
these RNA pieces, and the nuclease in turn destroys the foreign DNA, leading to an 
efficient immune defense.  
Since this system allows a targeted (by the guide RNA, gRNA) cutting of DNA by the 
nuclease, it provides a new tool to edit the genome of cell lines. To achieve this, a 
gene-specific gRNA gets co-expressed with the Cas 9 enzyme (consisting of two 
different nuclease domains), leading to a targeted double-strand DNA break (DSB), 
that is repaired by the error prone NHEJ (non-homologous end-joining) or HDR 
(homology-directed repair). NHEJ usually leads to small insertions or deletions, 
resulting in reading frame shifts and premature stop codons. Thereby the gene is 
functionally inactivated: a gene knockout. HDR uses a template to repair the DSB – 
giving also the opportunity to insert specific mutations or deletions by providing the 
desired sequence template (all reviewed by (Zhang, 2014)), a technique which was not 
applied in this thesis.  
We used the lentiCRISPRv2 system (Addgene # 52961 (Sanjana, 2014))  to 
knockout different PTP genes in our cell models. 
 
4.10.1 PTPRC knockout in K562 
Since the shRNA-mediated knockdown of PTPRC gave only poor knockdown 
efficiencies, stable PTPRC knockout cells were generated by infecting the parental 
cells with viral particles (chapter 4.8) freshly made from lentiCRISPR v2 plasmid 
(Addgene #52961,(Sanjana, 2014)) encoding target specific gRNA (two different target 
sequences, A and B) or lentiCRISPR v2 vector without an inserted gRNA (control). 
The final knockout vectors were made as follows: 
Two different guide sequences were used and the vector insert was made by 
annealing of two complementary DNA oligos (Sigma-Aldrich), that already comprise the 
sticky ends (underlined) needed for ligation into the target vector.  
“A”:  oligo A1: CACCGTTACCACATGTTGGCTTAGA   
oligo A2: AAACTCTAAGCCAACATGTGGTAAC 
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“B”:  oligo B1: CACCGTTAATATTAGATGTGCCACC 
 oligo B2: AAACGGTGGCACATCTAATATTAAC 
The annealed oligos were ligated into the empty lentiCRISPR v2 vector opened with 
BsmBI. The identity of the resulting vector was checked by control digest and 
sequencing (not shown).  
Infected cells were selected using 2 µg/ml puromycin, single cell clones were 
established by limited dilution, and clones were analyzed for absence of the target 
protein by flow cytometric analysis (chapter 4.11) and immunoblotting (chapter 4.13). 
Two independent knockout clones (A and B) were selected for further analysis. 
 
4.10.2 PTPN6 knockout in KCL-22  
Stable PTPN6 knockout cells were generated as described for PTPRC (chapter 
4.10.1). For PTPN6, only one guide sequence was used with success, obtained by 
annealing of the following oligos: 
Oligo 1: CACCGGAAGAACTTGCACCAGCGTC 
Oligo 2: AAACGACGCTGGTGCAAGTTCTTCC 
Infected cells were selected using puromycin (2 µg/µl), single cell clones were 
established by limited dilution, and clones were analyzed for absence of the target 
protein by immunoblotting (chapter 4.13). Two knockout clones (A and B) were 
selected for further analysis. 
 
4.11 Flow cytometric analysis of PTPRC 
Approximately 0.5 million cells were washed with 1 x cold PBS, and after taking the 
PBS off quantitatively, incubated with a solution of 39 µl PBS and 1 µl PTPRC-
APC/Cy7 (Biolegend, # 304014) on a turning wheel, at 4 °C for 30 min. After washing 
the cells twice with 1x PBS, the cells were suspended in 500 µl PBS and analyzed 
using BD FACS Canto II or BD Fortessa.    
 
4.12  IC50 assay 
A cell suspension with 100 000 cells/ml in full growth medium was prepared, and 
100 µl of this suspension were transferred to each well of rows A-G of black 96-well 
plates with clear bottom. For each inhibitor concentration, 995 µl RPMI medium were 
transferred into a 2 ml tube, and 5 µl of 1 000 x DMSO – inhibitor – stock (nilotinib [µM]: 
2 000, 500, 100, 20, 5, 1, 0.2; imatinib [mM]: 50, 10, 2, 0.5, 0.1, 0.02, 0.005; dasatinib 
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[µM]: 100, 20, 5, 1, 0.2, 0.05, 0.01) were added and mixed well. 300 µl of the resulting 
200 x inhibitor dilutions were transferred to one well of a standard 96 well cell culture 
plate, with the highest concentration in row A, and lowest in row G. Using an 8-
channel-pipette, 100 µl of respective dilution was taken up, and 4 times 25 µl were 
added to 4 wells (quadruplicates) each containing the 100 µl cell suspension. This 
results in 125 µl cell suspension with 10 000 cells, containing final concentrations of 
0.1 % DMSO and dose ranges of 0.2 nM to 2 µM nilotinib, 5 nM to 50 µM imatinib, and 
10 pM to 100 nM dasatinib. All wells of row H were filled with 125 µl full growth 
medium. Selected experiments were carried out with 11 different final nilotinib 
concentrations (0.2, 1, 2.5, 5, 7.5, 10, 15, 20, 50, 100, 2 000 nM).  
  
Figure 4-1.  (A) Photograph of a 96-well plate section 2 hours after CellTiter -Blue addition. Cells 
were seeded as described in the text, and treated with nilotinib in the indicated concentrations. 
Shown are quadruplicates of each condition.  (B) Graphical view of fitted dose response curve and 
IC50 calculation. Values of a representative experiment with 11 different nilotinib concentrations 
were used for IC50 calculation by Sigma Plot. The software fits the dose response curve and 
calculates the difference of maximum and minimum cell viability (difference between the two red 
dotted lines), and the inhibitor concentration, where 50 % of this are reached is reported as the IC50 
(yellow arrows).     
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After incubation at 37°C for 72 h, 25 µl of CellTiter-Blue reagent were added to each 
well containing cells, and to 4 wells containing 125 µl medium (blank), the plate was 
incubated at 37°C for 2 hours in the dark. Then, fluorescence (Ex 540 nm, Em 610 nm, 
Gain 35, top reading) was measured using a TECAN Infinite 200 (Tecan, Crailsheim, 
Germany) plate reader.  The measurement is based on the reduction of the component 
resazurin (dark blue, little intrinsic fluorescence) to resorufin (pink, high fluorescence) 
by metabolically active cells. The mean blank value was subtracted from each of the 
quadruplicates, and a mean fluorescence value was calculated. A photograph of an 
example plate showing the visible color shift from blue (blank and high nilotinib 
concentrations) to pink (lowest nilotinib concentration, most viable cells) in the wells 
with living cells is shown in Figure 4-1, A.  
IC50 values were calculated using Sigma Plot 13.0. Log10 of the respective inhibitor 
concentration was plotted against the corresponding mean fluorescence value, and the 
IC50 was calculated using the macro “ligand binding” with “sigmoidal dose-response 
(variable slope)” fitting. Figure 4-1, B shows an example of a fitted curve obtained from 
an experiment carried out with 11 different nilotinib concentrations and indicates the 
basis of the IC50 calculation.  
For the combination-treatment with idelalisib, a cell suspension containing 125 000 
cells/ml in full growth medium was prepared and 80 µl of this suspension were 
transferred into the black 96-well plate. For the samples containing a final 
concentration of 10 µM idelalisib, a dilution containing 62.5 µM idelalisib (with a DMSO 
concentration of 0.625 %) was prepared in full growth medium, and 20 µl of this was 
added to the cells. For the samples containing a final concentration of 1 µM idelalisib, a 
dilution containing 6.25 µM idelalisib was prepared, and 20 µl were added to the 
respective cells. Care was taken to have identical DMSO concentrations in all samples. 
Likewise, a growth medium solution containing only DMSO was prepared for the 
DMSO controls. To these 100 µl cell suspensions, 25 µl of the nilotinib dilutions (7 
concentrations, prepared as described above) were added, and the plate was treated 
exactly as described for the nilotinib-alone treatment.  
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4.13 Immunoblotting 
Cells were washed with ice-cold PBS and lysed on ice in RIPA lysis buffer 
containing “PhosSTOP” phosphatase inhibitor cocktail and “cOmplete” protease 
inhibitor cocktail diluted in RIPA lysis buffer according to the instructions of the 
manufacturer. The extracts were sonicated, and the cleared lysates were subjected to 
SDS-PAGE, using self made 10 % or 15 % gels (chapter 3.4), transferred to 
nitrocellulose membranes by tank blot (12 V over night), washed once in cold TBST, 
and blocked for 1 h at room temperature in the indicated blocking buffer (chapter 3.5). 
After washing 3 times for 10 minutes in cold TBST, membranes were incubated over 
night with the indicated primary antibodies at 4 °C. The membranes were incubated 
with the respective secondary antibody for 1 h at room temperature after washing off 
the primary antibody (3 x, 10 minutes, cold TBST). Detection was done using ECL 
solution and a LAS4000 system (Fujifilm). Membranes used to detect phospho-proteins 
were stripped for detection of respective total proteins by shaking the blots in stripping 
buffer at 55 °C for 25 min. After stripping, the blots were washed several times in water 
and TBST. The membranes were processed again as described above. 
 
4.14  Colony formation assay 
To prepare the methylcellulose master mix, 5 ml of 3 % methylcellulose stock were 
diluted with 5 ml IBM, 1.2 ml of heat inactivated FCS, and 120 µl P/S. All was mixed 
well using a 10 ml syringe. A cell suspension of 1 950 K562 cells in 50 µl of full growth 
medium was prepared in a 2 ml tube. After the bubbles had disappeared from the 
methylcellulose master mix, 1.2 ml of it were added to the prepared tube containing the 
cells, and everything was carefully resuspended using a 1 ml syringe. 500 µl of this cell 
suspension were added to two wells of a 24-well-plate each. After six days of 
cultivation at 37°C, 5 % CO2, in a humid chamber, 40 µl of a 4 mg/ml 
Iodonitrotetrazolium chloride solution were added dropwise onto the methylcellulose. 
The stained colonies were scanned using a HP Scanjet G4050 scanner with 1 200 dpi 
resolution after additional incubation over night at 37°C, 5 % CO2. Colony counting was 
done using NIH ImageJ 1.47v software. In general, colonies with a pixel size from 15-
100 and circularity from 0.5-1.0 were counted. Different cell types shown in one 
experiment were always processed in parallel. 
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5 Results 
5.1 PTP mRNA expression in patient leukocytes at start 
of treatment is associated with molecular response to 
nilotinib 
The total leukocytes of 66 CML patients before start of nilotinib study treatment were 
isolated, and the mRNA levels of 38 PTPs and two control genes were analyzed by 
qPCR (chapter 4.4). In addition, total leukocytes of 15 healthy donors were analyzed 
for PTP expression on mRNA level. Patient and healthy donor characteristics are 
shown in Table 5-1.  
To find out more about the influence of PTP expression status on nilotinib treatment 
outcome, we divided the CML patients in two groups according to whether or not the 
individual patient had reached a BCR-ABL1IS lower than 0.01 % (MR4 or better) after 
9 months of study treatment. Using these criteria, n=30 patients were in the BCR-
ABL1IS ≤ 0.01 % group, and n=36 in the BCR-ABL1IS > 0.01 % group respectively. The 
relative PTP mRNA levels of the analyses of all 66 patients (divided into these two 
groups) and 15 healthy donors are summarized in Figure 5-1. The PTPs are 
differentially expressed among healthy individuals and CML patients. Some of the 
PTPs show similar expression in healthy donors and CML patients (e. g. PTPN1, 
PTPN6, or DUSP2) and others show prominent differences (e. g. PTPN7, PTPN14, or 
CDC25A). After finishing the mRNA analysis of all 66 patient samples, the differences 
between the two CML patient groups were statistically evaluated by PD Dr. Markus 
Pfirrmann (Munich) and colleagues using univariate logistic regression analyses.  
 
Table 5-1. Patient and healthy donor characteristics.  
 
Patients  Healthy donors  
Total number  66  15  
Age  
Median 50 [19 – 72]  
IQR: [36 – 57]  
Median 54 [23 – 66]  
IQR [33 – 60]  
Gender  female n=18 (27.3 %)  female n=6 (40 %)  
EUTOS-Score  low risk n= 56 (84.8 %)  not applicable  
WBC x10
9
/L  
Median 48.45 [3.5 – 555]  
IQR: [18.95 – 160.55]*)  
not determined  
Platelets x10
9
/L  
Median 405.5 [93 – 3255] IQR: 
[256 – 670.5]*)  
not determined  
Hb g/dL  
Median 12.25 [8.3 – 16.2] IQR: 
[10.3 – 14]**)  
not determined  
*) 2 values missing; **) 4 values missing, IQR: interquartile range 
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Figure 5-1. PTPs are differentially expressed in healthy donors and CML patients. Total leukocytes 
of healthy donors (n=15) or 66 newly diagnosed CML patients (n=30 BCR-ABL1
IS
 ≤ 0.01 %, n=36 
BCR-ABL1
IS
 > 0.01 % after 9 months of study treatment) were isolated and mRNA levels of 38 
PTPs were analyzed using RT-qPCR. GUSB and B2M were used as control genes. Shown here 
are the mean relative mRNA levels of all 38 PTPs + standard deviation with technical duplicates for 
each PTP per individual. For more clarity, the PTPs with higher mRNA expression levels are shown 
in (A), and the PTPs with lower mRNA expression levels are shown in (B).  
 
 Results - 38 - 
 
Significant differences in the probability to reach MR4 or better after 9 months of 
nilotinib treatment were found in patients with higher mRNA levels of PTPRG and 
PTPRC (Figure 5-2, Table 5-2) as well as for PTPN13, PTPRA, and PTPRM (Table 5-
2). For all other PTPs, no significant differences were found in the final evaluation.  
Since the TIGER study protocol allowed inclusion of patients pretreated with imatinib or 
nilotinib for up to six weeks, and up to 6 months with hydroxyurea, we reassessed the 
actual treatment schedule of all 66 patients after unblinding and defined two sub-
cohorts of patients: in one cohort we excluded 12 of 66 patients that had been TKI 
pretreated, or discontinued nilotinib within the first 9 months of treatment (cohort size 
n=54), in the second cohort, we additionally excluded all patients pretreated with 
hydroxyurea for more than 2 days, and patients that reduced nilotinib dose for more 
than 3 weeks (cohort size n=35). These two patient cohorts were used to validate the 
statistical significance of the 5 PTPs found in the 66 patient screen: significances for 
PTPRA, PTPRC, and PTPRG were still found in the two more stringently defined 
cohorts, but were lost for PTPRM in the n=54 patient group, and for PTPN13 in both 
newly defined sub-groups (Figure 5-2, Table 5-2).  
 
 
  
Table 5-2. Odds ratios in univariate logistic regression on the probability to be in MR
4
 (BCR-ABL1
IS
 
≤ 0.01 %) 9 months after start of nilotinib therapy. 
 
Patient 
cohorts, 
number of 
patients (n) 
PTP Odds ratio 
Lower 95% 
confidence 
limit for odds 
ratio 
Upper 95% 
confidence 
limit for odds 
ratio 
P value  
likelihood ratio 
test 
n=66  
PTPN13  1.045  1.009  1.092  0.0122  
PTPRA  1.275  1.073  1.561  0.0047  
PTPRC  1.015  1.005  1.028  0.0024  
PTPRG  1.046  1.013  1.088  0.0039  
PTPRM  1.019  1.004  1.038  0.0154  
n=54  
PTPN13  1.040  0.995  1.093  0.0834  
PTPRA  1.287  1.056  1.628  0.0112  
PTPRC  1.013  1.001  1.027  0.0389  
PTPRG  1.059  1.015  1.116  0.0064  
PTPRM  1.012  0.995  1.031  0.1748  
n=35  
PTPN13  1.039  0.990  1.103  0.1242  
PTPRA  1.344  1.060  1.826  0.0123  
PTPRC  1.014  1.000  1.031  0.0430  
PTPRG  1.087  1.026  1.175  0.0023  
PTPRM  1.032  1.005  1.069  0.0168  
PTPs analyzed in cell based assays are highlighted. 
For cohort details see legend Figure 5-2 and text chapter 5.1. 
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Figure 5-2. Expression levels of PTPRG and PTPRC are associated with response after 9 months 
of nilotinib treatment. The RNA of total, peripheral blood leukocytes of CML patients in chronic 
phase was isolated and mRNA expression levels of 38 PTPs were analyzed. GUSB and B2M were 
used as control genes.  
(A) 66 patients were grouped according to their individual BCR-ABL1
IS
 (MR
4
, yes or no) after 
9 months of nilotinib treatment. The mRNA levels for PTPRG and PTPRC are shown. Since the 
TIGER study protocol allowed pretreatments with TKI and HU, we reassessed the actual treatment 
schedule of all 66 patients after unblinding. We defined two sub-cohorts of patients: (B) in one 
cohort we excluded 12 of 66 patients that had TKI pretreatments or discontinued the study 
treatment (total n=54), (C) In the second cohort, we additionally excluded 19 patients (total n=35), 
resulting in a cohort of patients with no TKI pretreatment, with no more than 2 days of HU 
pretreatment, and no nilotinib dose reductions for more than 3 weeks.  
Each point represents the relative PTP expression value of one patient, bars show mean values  
+/- standard deviation. Differences in PTP mRNA expression between the patient groups were 
statistically tested. * if p < 0.05; ** if p < 0.01. P values were calculated using the likelihood ratio 
test. For details and confidence limits see Table 5-2.  
* This and other figures, as well as some parts of the text of this thesis were already 
published  in  (Drube, 2018).   
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5.2 Functional analysis of PTP knockdown CML cell lines 
In order to start functional analyses as early as possible, I performed preliminary 
statistical analyses (not shown) comparing PTP expression levels of patients before all 
66 patient samples were available. Based on these preliminary analyses and literature 
reports, PTPN6, PTPN12, PTPRC, PTPRE, PTPRG, DUSP1, PTP4A2, and ACP1 
were chosen for an initial functional analysis in CML cell lines. As cell line models, we 
chose the widely used CML cell lines K562 and KCL-22 for our assays. Similar to the 
PTP expression pattern of the healthy individuals and CML patients, the CML cell lines 
show a distinct individual expression pattern (Figure 5-3). For example PTPN6, 
PTPN13, PTPRE, and PTPRG are higher expressed, but PTPRB is much lower 
expressed in KCL-22 compared to K562 cells. PTPN12, PTPRC, DUSP1, PTP4A2, 
and ACP1 are similarly expressed in both cell lines.     
To directly assess the influence of single PTPs on treatment outcome, stable 
shRNA-mediated knockdown cell lines or PTP over-expressing cell lines were created. 
In the patient samples, PTPRG was only expressed at a very low level. To further 
analyze this PTP, we chose to establish a PTPRG over-expressing K562 cell-model 
(see chapter 5.4). For the other seven selected PTPs, three different shRNA constructs 
were used to generate stable knockdown cell lines, and the remaining PTP levels were 
determined on mRNA level. Since in the K562 cells, PTPN6 and PTPRE are only lowly 
expressed (Figure 5-3, Figure 5-9, A), these two PTPs were only knocked down in 
KCL-22. Table 5-3 summarizes the used constructs and the remaining PTP expression 
levels after stable transduction of the shRNAs. For PTPRE, DUSP1, and PTP4A2, no 
more analysis was carried out, since the knockdown efficiency could not be improved 
in subsequent experiments (data not shown). For PTPN6, PTPN12, PTPRC, and 
ACP1, the cell pools highlighted in Table 5-3 were analyzed for the change in the IC50s 
of nilotinib, imatinib, and dasatinib compared to control cell lines. The results of the two 
experiments carried out with K562-ACP1 (Figure 5-4, A) and KCL-22-PTPN12 (Figure 
5-4, B) knockdowns did not show consistent IC50 changes. These PTPs were not 
further analyzed. In contrast, the knockdown of PTPRC in K562 cells resulted in IC50 
reductions in all tested TKI in both experiments (Figure 5-5). Since this result was 
obtained with PTPRC mRNA reductions of only about 40 %, that could not be further 
improved by new transductions, we decided to carry out CRISPR/Cas9-mediated 
knockout of PTPRC to analyze the influence of this PTP on TKI susceptibility (see 
chapter 5.5). Following up PTPRC was also prompted, because it was one of the 
phosphatases with a significant correlation of mRNA level to reaching an MR4 after 
9 months of nilotinib treatment in the final patient-analysis.  
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Figure 5-3. PTPs are differentially expressed in CML cell lines. 
(A) The PTP mRNA expression status of the Ph
+
 (BCR-ABL1, “b3a2”) CML cell line K562 (derived 
from a 53-year-old female at CML blast crisis) was analyzed. GUSB and B2M were used as control 
genes. Shown are the mean relative expression values of n=4 independent measurements with 
technical duplicates + standard deviation (SD). 
(B) The PTP mRNA expression status of the Ph
+
 (BCR-ABL1, “b2a2”) CML cell line KCL-22 
(derived from a 32-year-old female at CML blast crisis) was analyzed. GUSB and B2M were used 
as control genes. Shown are the mean relative expression values of n=4 independent 
measurements with technical duplicates + standard deviation. 
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Using PTPN6 knockdown in KCL-22 cells, no clear answer to the question of 
whether or not it plays a role for treatment sensitivity was found. In nilotinib-treated 
cells, we saw a reduction of the IC50 in 5 of 6 experiments (with two different shRNAs), 
in imatinib-treated cells, we saw an increase in one cell pool, and a decrease in a cell 
pool generated using a different shRNA. Dasatinib-treated cells did also not seem to 
show any clear difference (Figure 5-6). Given these ambiguous first results, and the 
literature reports claiming a role of PTPN6 in imatinib treatment response, we chose to 
further analyze the influence of this PTP in more detail (chapter 5.3). 
Table 5-3. Knockdown efficiencies of PTP genes in K562 and KCL-22 cells.     
Gene  
shRNA pLKO.1 
construct number 
(only last digits) 
Remaining relative expression 
K562 KCL-22 
PTPN6  
6885 - 0.30 
6886 - 0.48 
11052 - 0.73 
PTPN12  
2830 0.67 0.33 
2831 0.77 0.31 
2832 0.87 0.39 
PTPRC  
2845 0.64 0.57 
2847 0.92 0.71 
2848 0.59 1.06 
PTPRE  
2893 - 0.92 
2894 - 0.63 
2896 - 0.61 
DUSP1  
2514 1.15 1.03 
2516 0.79 0.61 
2518 1.34 1.15 
PTP4A2  
2924 1.15 0.62 
2926 0.72 0.55 
2927 0.86 0.65 
ACP1  
2598 0.56 0.81 
2599 1.07 1.20 
2600 0.20 0.91 
The cell pools highlighted were used for IC50 analyses in cell based assays  
(Figures 5-4, 5-5, and 5-6). 
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Figure 5-4. Knockdown of ACP1 or PTPN12 did not influence the TKI sensitivity in CML cell lines. 
(A) K562 cells with ACP1 knockdown (Table 5-3) were analyzed for the IC50 of nilotinib, imatinib, 
and dasatinib. Two independent experiments with quadruplicate technical replicas were carried out. 
One arrow represents one experiment. 
(B) Two different cell pools of KCL-22 cells with PTPN12 knockdown (Table 5-3) were analyzed for 
the IC50 of nilotinib, imatinib, and dasatinib. One independent experiment of each cell pool 
(distinguished by color) with quadruplicate technical replicas was carried out. One arrow represents 
one experiment. 
      
 
Figure 5-5. Knockdown of PTPRC did increase the TKI sensitivity in CML cell lines. K562 cells with 
PTPRC knockdown (Table 5-3) were analyzed for the IC50 of nilotinib, imatinib, and dasatinib. Two 
independent experiments with quadruplicate technical replicas were carried out. One arrow 
represents one experiment. 
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5.3 The role of PTPN6 for TKI treatment response   
PTPN6 was not found to be associated with treatment outcome in our patient cohort 
(Figure 5-7) and the PTPN6-shRNA knockdown approach did neither clearly support, 
nor disagree with the literature reports on the influence of this PTP on the IC50 of the 
three tested TKI (see chapter 5.2). We therefore chose to include PTPN6 in a 
CRISPR/Cas9 knockout approach, to further clarify the role of PTPN6 on treatment 
response. Two CRISPR/Cas9 knockout cell clones (PTPN6-KO A and B) of KCL-22 
cells were created and the knockout was confirmed by western blot (Figure 5-8, A). 
These cells and control cells transduced with the CRISPR/Cas9 vector lacking a guide 
RNA were analyzed for their IC50 of nilotinib, imatinib, and dasatinib (Figure 5-8, B). 
Again, comparable to the results in the shRNA knockdown experiments, no consistant 
change in the IC50 values was found in the knockout cell clones. In addition to the 
knockdown/knockout approaches, PTPN6 was over-expressed in K562 cells. These 
Figure 5-6. PTPN6 might influence the sensitivity of CML cells to TKI inhibitors.  
Two different cell pools of KCL-22 cells with PTPN6 knockdown (Table 5-3) were analyzed for the 
IC50 of nilotinib, imatinib, and dasatinib. Three independent experiments of each cell pool 
(distinguished by color) with quadruplicate technical replicas were carried out. One arrow 
represents one experiment. 
      
 
Figure 5-7: Expression level of PTPN6 is not associated with 
response after 9 months of nilotinib treatment. The RNA of total, 
peripheral blood leukocytes of CML patients in chronic phase was 
isolated and mRNA expression levels of 38 PTPs were analyzed. 
GUSB and B2M were used as control genes. Shown here is the 
PTPN6 mRNA level of 66 patients grouped according to their 
individual BCR-ABL1
IS
 (MR
4
 yes or no) after 9 months of nilotinib 
treatment. Each point represents the relative PTP expression value of 
one patient, bars show mean values +/- standard deviation (SD). 
Differences in PTP mRNA expression between the patient groups 
were statistically tested. Not significant (ns), if p > 0.05. P values were 
calculated using the likelihood ratio test.  
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cells do express only very little endogenous PTPN6 (Figure 5-3, A; Figure 5-9, A). 
We transduced the cells with either the empty vector (EV), or PTPN6 wild type (WT), 
or the catalytically inactive PTPN6-C453S (CS) mutant constructs. The expression 
level of both PTPN6 constructs was similar (Figure 5-9, A). These three cell pools were 
also analyzed for their IC50 of the three TKI (Figure 5-9, B). The over-expression of 
PTPN6 did not alter the IC50 of the analyzed K562 cells.   
 
  
Figure 5-9. PTPN6 expression and response of CML cells to TKI. 
K562 cells with low endogenous PTPN6 expression were stably 
transduced with either empty vector (EV), wild type PTPN6 (WT), 
or the catalytically inactive PTPN6-C453S (CS) mutant. (A) Protein 
expression was analyzed by western blot. (B) The engineered cells 
were analyzed for IC50 of nilotinib, imatinib, and dasatinib. Each dot 
represents the IC50 value determined in one independent 
experiment with quadruplicate technical replicas, black bars show 
the median of n=3 independent experiments. 
 
Figure 5-8. PTPN6 expression and response of CML cells to TKI. 
KCL-22 cells were subjected to CRISPR/Cas9-mediated knockout 
of the PTPN6 gene. (A) Two individual single cell clones were 
analyzed for PTPN6 expression using western blot. (B) The 
engineered cells were analyzed for IC50 of nilotinib, imatinib, and 
dasatinib. Each dot represents the IC50 value determined in one 
independent experiment with quadruplicate technical replicas, 
black bars show the median of n=3 independent experiments. 
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Figure 5-10. Stable over-expression of PTPRG-wild type (WT) and the 
phosphatase-dead mutant PTPRG-C1060S (CS) result in similar PTPRG 
expression levels. K562 cells were transduced with viral particles, resulting 
in the over-expression of PTPRG-WT or PTPRG-CS, or with viral particles 
made from respective empty vector (EV).  
 
5.4 PTPRG increases nilotinib and imatinib treatment 
response, decreases clonogenic capacity, and 
modulates signal transduction of CML cells 
In order to study the influence of PTPRG on treatment response, cells over-
expressing either PTPRG wild type (WT), or the catalytically inactive PTPRG – C1060S 
(CS) mutant, or the respective empty vector (EV) were established. To initially 
characterize the PTPRG constructs, HEK293 cells were transiently transfected with 
PTPRG-WT or PTPRG-CS in combination with EGFR (Epidermal growth factor 
receptor), a PTPRG target (den Hertog, 2008). PTPRG-WT expressing cells showed 
prominent de-phosphorylation of EGFR, whereas PTPRG-CS cells did not show this 
activity, confirming the functionality of both constructs (data by B. V. Albert, a M.Sc. 
student in our lab (Albert, 2017), not shown).  
I engineered K562 cells to obtain cell pools stably expressing empty vector (EV), or 
similar levels of PTPRG-WT or PTPRG-CS (Figure 5-10). They were subjected to IC50 
assays with nilotinib, imatinib, and dasatinib. Fitted curves of one representative 
nilotinib experiment are shown in Figure 5-11, A. Note that only the concentration 
range from 2.5 nM to 50 nM is shown. IC50 values of n=6 independent experiments are 
shown for nilotinib (Figure 5-11, B), imatinib (Figure 5-11, C), and dasatinib (Figure 5-
11, D). In case of nilotinib and imatinib, PTPRG-WT reduced the IC50 significantly 
compared to EV-cells, but in dasatinib-treated cells, no significant change of the IC50 
was detectable. For two experiments carried out with 11 different nilotinib 
concentrations, the 95 % confidence intervals of the IC50 values were determined and 
are reported in Table 5-4. The 95 % confidence intervals of the PTPRG-WT IC50s are 
not overlapping with the confidence intervals of EV or PTPRG-CS. The mean reduction 
of the IC50 for nilotinib compared to EV cells of the 6 experiments shown in Figure 5-11, 
B was 21.3 % in PTPRG-WT- and only 4 % in the PTPRG-CS-expressing cells, 
indicating a PTP activity dependent mechanism (Table 5-5).  
Next, we wanted to analyze, whether PTPRG over-expression can also interfere 
with the BCR-ABL1 driven transforming capacity. Therefore colony formation assays 
were performed. We analyzed our engineered K562 cells for their ability to form 
colonies in methylcellulose. The cells were grown in methylcellulose in presence of 
10 % serum for 7 days and colony numbers were counted. I performed six independent 
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Figure 5-11. PTPRG modulates nilotinib and imatinib response in cell lines. (A) Fitted curves of 
one representative IC50 analysis carried out with 11 different nilotinib concentrations are shown. For 
more clarity, only dose ranges from 2.5 nM to 50 nM are presented.  
IC50 analyses for nilotinib (B), imatinib (C), and dasatinib (D) were carried out with K562 cells stably 
expressing wild type PTPRG (WT) or catalytically inactive PTPRG-C1060S mutant (CS). PTPRG 
protein levels of engineered cells are shown in Figure 5-10. Each dot represents the IC50 value 
determined in one independent experiment with quadruplicate technical replicas, black bars show 
the median of n=6 independent experiments. Not significant (ns), if p > 0.05; * if p < 0.05. 
Comparison with the EV expressing cells was performed with the Wilcoxon matched-pairs test. 
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experiments, and found a significant decrease in colony numbers of cells expressing 
PTPRG-WT compared to EV transduced cells, but no significant change when 
comparing control cells with cells expressing the mutant PTPRG-CS (Figure 5-12). 
To get more information on the signaling cascades that might be involved in 
modulation of IC50 and colony formation, a screen for possible signaling molecules was 
done (data not shown). We decided to analyze BCR-ABL1 auto-phosphorylation, 
phosphorylation of SFK (especially cSRC and Lyn), STAT5, and ERK 1/2, and 
expression of p27 and Bcl-2 in more detail. 
We followed two different approaches: First, the cells were analyzed after 4 h 
starvation from serum (4 h SFM, serum-free medium) in order to see effects that might 
otherwise be covered up by serum induced signaling (Figure 5-13). Second, cells were 
analyzed after 24 h of treatment with nilotinib or DMSO in presence of full growth 
medium, similar to the treatment in the IC50 assays (Figure 5-14). In the absence of 
serum (Figure 5-13), a decreased BCR-ABL1 auto-phosphorylation is visible in cells 
over-expressing PTPRG-WT, but not in cells expressing PTPRG-CS. The 
phosphorylation of SFK was analyzed and membranes were reprobed with specific 
antibodies for cSRC and Lyn, two SFK-members fitting to the molecular weights of the 
Table 5-4. IC50s for nilotinib of K562 cells transduced with empty vector, PTPRG-
WT, or PTPRG-CS, and respective 95 % confidence intervals of two 
representative experiments carried out with 11 nilotinib concentrations.  
Nilotinib 
Experiment A Experiment B 
IC
50
 [nM] 95 % confidence 
intervals  
IC
50
 [nM] 95 % confidence 
intervals 
EV 12.5  11.49 to 13.59 12.07 11.18 to 13.03  
PTPRG-WT 10.09  9.785 to 10.41 9.515 8.614 to 10.51  
PTPRG-CS 12.62  11.54 to 13.8 12.13 11.17 to 13.17  
 
 
Table 5-5. Relative reductions of IC50s for nilotinib compared to 
EV expressing K562 cells for the experiments shown in Figure 5-
11 (B).  
Nilotinib 
IC50 % reduction EV vs. 
PTPRG-WT PTPRG-CS 
Experiment 1 33.0 13.2 
Experiment 2 12.1 -5.9 
Experiment 3 23.2 12.5 
Experiment 4 19.3 -1.0 
Experiment 5 21.2 -0.5 
Experiment 6 19.2 5.7 
Mean % reduction 
compared to EV 
21.3 4.0 
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Figure 5-12. PTPRG attenuates BCR-ABL1 
dependent cell transformation. K562 over-
expressing PTPRG-WT or PTPRG-CS were 
analyzed for colony formation in methyl 
cellulose. Representative images of colonies are 
shown. Each triangle represents colony count 
per well (mean of duplicates of an individual 
experiment). Black bars represent the median of 
n=6 independent experiments. Not significant 
(ns), if p > 0.05; * if p < 0.05. Comparison with 
EV cells was performed with the Wilcoxon 
matched-pairs test. 
 
detected phospho-SFK signals. A reduction of the pLyn signal was again found in the 
PTPRG-WT expressing cells, but not in PTPRG-CS expressing cells. The 
phosphorylation of ERK 1/2 tended to be affected in the same direction. In presence of 
serum (Figure 5-14, DMSO treatment), most of the described signaling modulations by 
PTPRG are not visible. They are possibly covered up by serum stimulation. Only the 
phosphorylation of ERK 1/2 appears moderately diminished in presence of PTPRG-
WT. In presence of nilotinib (Figure 5-14, nilotinib treatment), the activation of most 
signaling mediators was eliminated; only the inhibition of SFK phosphorylation was 
partial. The signal for p27 strongly increased with the nilotinib treatment.   
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Figure 5-13. PTPRG over-expression 
attenuates BCR-ABL1 signal transduction. 
K562 cells over-expressing PTPRG-WT or 
PTPRG-CS were starved from serum for 4h 
(SFM). (A) Cell lysates were prepared and 
subjected to SDS-PAGE and immunoblotting 
with the indicated antibodies. Total protein was 
detected after stripping off the respective 
phospho-specific antibodies.  Representative 
blots of n=3 independent experiments are 
shown.  
(B) Quantification of blots from n=3 
independent experiments: For BCR-ABL1, 
cSRC, Lyn, STAT5, and ERK 1/2, the phospho-
signal was divided by the respective total 
protein signal. For p27 and Bcl-2, the specific 
signal was divided by the actin signal. The 
signals for PTPRG-WT and PTPRG-CS are 
reported relative to the EV cell signals of each 
experiment. Shown is the mean relative 
intensity of n=3 independent experiments +/- 
standard deviation.  
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Figure 5-14. Nilotinib treatment and PTPRG over-
expression affect BCR-ABL1 signal transduction in 
the same direction. (A) K562 cells over-expressing 
PTPRG-WT or PTPRG-CS were treated with 
nilotinib (1 µM, 24 h) or DMSO in presence of 10 % 
FCS. Cell lysates were prepared and subjected to 
SDS-PAGE and immunoblotting with the indicated 
antibodies. Total protein was detected after 
stripping off the respective phospho-specific 
antibodies.  Representative blots of n=3 
independent experiments are shown.  
(B) Quantification of blots from n=3 independent 
experiments: For BCR-ABL1, cSRC, Lyn, STAT5, 
and ERK 1/2, the phospho-signal was divided by 
the respective total protein signal. For p27 and Bcl-
2, the specific signal was divided by the actin 
signal. All signals are reported relative to the 
DMSO treated EV cell signals of the respective 
experiment. Shown is the mean relative intensity of 
n=3 independent experiments +/- standard 
deviation.  
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5.5 PTPRC decreases sensitivity to nilotinib and imatinib, 
increases the clonogenic capacity, and abrogates 
BCR-ABL1 signal transduction 
In the shRNA-mediated knockdowns of PTPRC in K562 cells, a decrease of the IC50 
for all tested TKI was seen, although the remaining mRNA expression of PTPRC was 
still around 60 % after knockdown. This observation suggested that PTPRC may in fact 
negatively affect the intrinsic sensitivity of CML cells to TKIs. In order to validate these 
findings, K562 cells with a CRISPR/Cas9-mediated PTPRC-knockout were created. 
Two single cell clones (KO A and B) were established, and one of them was 
additionally used to exogenously re-express PTPRC (KO A +PTPRC), or as control, 
was transduced with viral particles made from respective empty vector (KO A + EV). 
The cells were characterized for total protein expression by western blotting analysis 
(Figure 5-15, A). In the knockout cells, no PTPRC signal was detected, and the 
exogenous re-expression of PTPRC led to an expression level similar to that of the 
control cells, that were transduced with the CRISPR/Cas9 construct lacking a gRNA. 
The surface expression was analyzed by flow cytometry using a PTPRC specific 
antibody (Figure 5-15, B). The two knockout-cell lines, as well as the knockout cell line 
transduced with the empty vector did not have any PTPRC surface staining 
(comparable to unstained cells). The control- and PTPRC re-expressing cell lines 
expressed comparable PTPRC levels.  
The PTPRC knockout- and re-expressing cells were subjected to the same analyses 
as described for the PTPRG over-expressing cells in chapter 5.4.  
  Figure 5-15. PTPRC knockout cells (PTPRC-KO A, PTPRC-KO 
B, and KO A + EV) show no PTPRC expression in total lysates 
and flow cytometric analysis, PTPRC re-expressing cells (KO A + 
PTPRC) have similar total PTPRC protein levels and surface 
expression levels comparable to the control cell line. Two K562 
single cell clones with PTPRC knockout (PTPRC-KO A and 
PTPRC-KO B) were established. PTPRC-KO A was used to 
exogenously re-express PTPRC (KO A + PTPRC). The 
respective control was obtained by transducing the knockout cells 
with the corresponding empty vector (KO A + EV). The cells were 
subjected to analysis by immunoblotting (A) or flow cytometry 
(B).  
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First, the susceptibility of the engineered cell lines to TKI was tested using the IC50 
assay. In Figure 5-16, A, representative fitted curves for IC50 assays carried out with 
nilotinib-treated cells show a shift to the left (lower nilotinib concentrations) of the 
PTPRC knockout cell lines. For two representative experiments carried out with 11 
different nilotinib concentrations, the calculated IC50 values and their corresponding 
95 % confidence intervals are shown in Table 5-6. The confidence intervals of the 
PTPRC expressing cells (control and KO A + PTPRC) are not overlapping with the 
intervals calculated from the PTPRC knockout cell lines (PTPRC-KO A, PTPRC-KO B, 
and KO A + EV). In Figure 5-16, B, C, and D, calculated IC50 values of six independent 
experiments for nilotinib, imatinib, and dasatinib are shown respectively. The IC50 
values of nilotinib and imatinib were significantly lower in the cell lines lacking PTPRC. 
In the dasatinib-treated cells, the IC50 was affected to a lesser extent. A significant 
difference was observed only for one of the tested knockout cell lines. PTPRC 
knockout led to a mean nilotinib IC50 reduction of 23.2 – 27.6 % compared to the 
control cell line, and the re-expression of PTPRC led to an increase of the IC50 back to 
the levels of control cells (Table 5-7).  
Similar to the analyses in PTPRG-expressing cells, we addressed the question, 
whether the PTPRC-KO does have an impact on the BCR-ABL1 driven transforming 
capacity, in absence of TKI. The control and PTPRC-KO cells were therefore analyzed 
for their colony forming capacity in methylcellulose. The PTPRC knockout cells formed 
significantly less colonies within 7 days of cultivation compared to the PTPRC 
expressing control cells (Figure 5-17, A). The transduction of the PTPRC knockout 
cells with the empty lentiviral control vector already led to an increase in colony 
formation of the KO A + EV cells probably caused by the required second round of 
lentiviral transduction. However, even this elevated colony formation could be 
moderately, but significantly further enhanced by PTPRC expression (Figure 5-17, B).  
In order to analyze the signaling proteins that might be involved in the mediation of 
the described differences between PTPRC expressing and PTPRC knockout cells, we 
analyzed the cells by western blotting, under the two conditions already described for 
the PTPRG expressing cells. The cells were cultivated for 4 h in SFM (Figure 5-18), or 
for 24 h in presence of 10 % FCS and DMSO or nilotinib (Figure 5-19) and cell lysates 
were analyzed for the signaling molecules introduced in chapter 5.4.           
The phosphorylation of BCR-ABL1 was moderately increased in the PTPRC 
knockout cells, both in presence and absence of serum. Absence of PTPRC led also to 
an increase in ERK 1/2 phosphorylation under both conditions, with even stronger 
phosphorylation signals in presence of serum (Figures 5-17 and 5-18).  
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Figure 5-16. PTPRC modulates nilotinib and imatinib response in cell lines. (A) Fitted curves of 
one representative IC50 analysis carried out with 11 different nilotinib concentrations are shown. For 
more clarity, only dose ranges from 2.5 nM to 50 nM are presented.  
IC50 analyses for nilotinib (B), imatinib (C), and dasatinib (D) were carried out with two individual 
clones (A and B) of K562 cells obtained by CRISPR/Cas9-mediated knockout of the PTPRC gene 
and corresponding control cells. Additionally, PTPRC-KO clone A was used to re-express PTPRC 
by lentiviral transduction (KO A + PTPRC; control: KO A + EV (empty vector)) PTPRC protein 
levels of engineered cells are shown in Figure 5-15. Each dot represents the IC50 value determined 
in one independent experiment with quadruplicate technical replicas, black bars show the median 
of n=6 independent experiments. Not significant (ns), if p > 0.05; * if p < 0.05. Comparison with the 
EV cells was performed with the Wilcoxon matched-pairs test. 
 
Table 5-6. IC50s for nilotinib of PTPRC knockout cell clones and re-expressing cells and 
respective 95 % confidence intervals of two representative experiments carried out with 
11 nilotinib concentrations.  
Nilotinib 
Experiment A Experiment B 
IC50 [nM] 
95 % confidence 
intervals 
IC50 [nM] 
95 % confidence 
intervals 
control 13.39 12.11 to 14.8 12.29 11.08 to 13.62 
PTPRC-KO A 9.706 9.25 to 10.18 9.87 8.985 to 10.84 
PTPRC-KO B 8.726 8.522 to 8.934 8.51 8.052 to 8.995 
KO A + EV 9.791 9.353 to 10.25 9.247 8.618 to 9.921 
KO A + PTPRC 12.58 11.92 to 13.28 12.74 11.99 to 13.53 
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In nilotinib-treated cells, the BCR-ABL1 phosphorylation was completely abolished 
in all cell lines and also the ERK 1/2 signal was strongly reduced. The phosphorylation 
of the SFKs cSRC and Lyn was reduced in the PTPRC knockout cells, most 
prominently seen in absence of serum. The expression of the cell cycle inhibitor p27 
was elevated in the engineered knockout cell lines, which was seen only in presence of 
serum (Figure 5-19, DMSO). This elevation was further promoted by nilotinib treatment. 
Importantly, all PTPRC knockout effects were rescued by the exogenous re-expression 
of PTPRC in one of the knockout clones.       
 
Figure 5-17. PTPRC promotes BCR-ABL1 dependent cell transformation. K562 PTPRC knockout 
clones A and B (A), or PTPRC re-expressing cells (KO A + PTPRC) (B) were analyzed for colony 
formation in methyl cellulose. Representative images of colonies are shown. Each triangle 
represents colony count per well (mean of duplicates of an individual experiment). Black bars 
represent the median of n=6 independent experiments. * if p < 0.05. Comparison with 
CRISPR/Cas9 control (A) or PTPRC KO A cells transduced with empty vector (KO A + EV) (B) was 
performed with the Wilcoxon matched-pairs test. 
 
 
Table 5-7. Relative nilotinib IC50 reductions compared to CRISPR/Cas9 control K562 cells for the 
experiments shown in Figure 5-16 B.  
Nilotinib 
IC50 % reduction control vs. 
PTPRC-KO A PTPRC-KO B KO A + EV KO A + PTPRC 
Experiment 1 17.0 26.7 28.0 -23.0 
Experiment 2 31.6 22.8 33.1 15.4 
Experiment 3 27.1 26.0 16.0 -5.3 
Experiment 4 19.0 24.3 10.4 -2.6 
Experiment 5 27.5 34.8 26.9 6.0 
Experiment 6 19.7 30.8 24.8 -3.7 
Mean % reduction 
compared to control 
23.7 27.6 23.2 -2.2 
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Figure 5-18. PTPRC deficiency affects 
aspects of BCR-ABL1 signal transduction 
differently. (A) K562 cells with PTPRC 
knockout and respective PTPRC re-
expressing cells were starved from serum for 
4h (SFM). Cell lysates were prepared and 
subjected to SDS-PAGE and immunoblotting 
with the indicated antibodies. Total protein 
was detected after stripping off the respective 
phospho-specific antibodies.  Representative 
blots of n=3 independent experiments are 
shown.  
(B) Quantification of blots from n=3 
independent experiments: For BCR-ABL1, 
cSRC, Lyn, STAT5, and ERK 1/2, the 
phospho-signal was divided by the respective 
total protein signal. For p27 and Bcl-2, the 
specific signal was divided by actin signal. 
The signals of engineered PTPRC KO and 
re-expressing cells are reported relative to 
the control cell signals of each experiment. 
Shown is the mean relative intensity of n=3 
independent experiments +/- standard 
deviation. 
 
Figure 5-18. PTPRC deficiency affects 
aspects of BCR-ABL1 signal transduction 
differently. (A) K562 cells with PTPRC 
knockout and respective PTPRC re-
expressing cells were starved from serum for 
4h (SFM). Cell lysates were prepared and 
subjected to SDS-PAGE and immunoblotting 
with the indicated antibodies. Total protein 
was detected after stripping off the respective 
phospho-specific antibodies.  Representative 
blots of n=3 independent experiments are 
shown.  
(B) Quantification of blots from n=3 
independent experiments: For BCR-ABL1, 
cSRC, Lyn, STAT5, and ERK 1/2, the 
phospho-signal was divided by the respective 
total protein signal. For p27 and Bcl-2, the 
specific signal was divided by actin signal. 
The signals of engineered PTPRC KO and 
re-expressing cells are reported relative to 
the control cell signals of each experiment. 
Shown is the mean relative intensity of n=3 
independent experiments +/- standard 
deviation. 
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Figure 5-19. Nilotinib treatment and 
PTPRC deficiency affect aspects of 
BCR-ABL1 signal transduction in the 
same direction. (A) K562 cells with 
PTPRC knockout and respective 
PTPRC re-expressing cells were 
treated with nilotinib (1 µM, 24 h) or 
DMSO in presence of 10 % FCS. Cell 
lysates were prepared and subjected 
to SDS-PAGE and immunoblotting 
with the indicated antibodies. Total 
protein was detected after stripping off 
the respective phospho-specific 
antibodies.  Representative blots of 
n=3 independent experiments are 
shown.  
(B) Quantification of blots from n=3 
independent experiments: For BCR-
ABL1, cSRC, Lyn, STAT5, and ERK 
1/2, the phospho-signal was divided 
by the respective total protein signal. 
For p27 and Bcl-2, the specific signal 
was divided by actin signal. All signals 
are reported relative to the DMSO 
treated control cell signals of the 
respective experiment. Shown is the 
mean relative intensity of n=3 
independent experiments +/- standard 
deviation.  
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Figure 5-20. The phosphoinositide 3-kinase δ 
inhibitor idelalisib promotes the response of CML 
cells to nilotinib. (A) K562 cells were subjected to a 
nilotinib IC50 assay in presence of either 1 µM or 
10 µM idelalisib or vehicle control (DMSO), as 
indicated. Arrows indicate the change of IC50 with 
idelalisib treatment. Each pair of arrows symbolizes 
one independent experiment. (B) K562 cells were 
treated with idelalisib (1 µM or 10 µM) or DMSO in 
presence of 10 % FCS for 24h. Lysates were 
subjected to SDS-PAGE and immunoblotting. 
Shown are blots, which are representative of two 
independent experiments.  
 
5.6 Combination-therapy approaches 
The PTPRC knockout cells have an increased sensitivity to the TKI nilotinib (chapter 
5.5) and these cells have a higher expression of p27 than the control cells (Figure 5-
19). In addition, p27 levels increase upon nilotinib treatment. I therefore considered a 
combination-treatment of nilotinib with a p27-inducing agent might be beneficial to the 
treatment outcome.    
P27 is known to be negatively regulated by PI3K (phosphoinositide 3-kinase) 
signaling (Crivellaro, 2016). An abundant PI3K in hematopoietic cells is PI3Kδ. The 
PI3Kδ inhibitor idelalisib (CAL-101, GS-1101) which is approved for treatment of B-cell 
leukemia/lymphoma, has recently been shown to cause elevation of p27 in CML 
cells (Chen, 2016). In this thesis, a combination approach of the TKI nilotinib together 
with the PI3Kδ inhibitor idelalisib was tested in the IC50 assay for parental K562 cells. 
The IC50 assay was carried out with the 7 standard concentrations of nilotinib in 
presence of either DMSO (vehicle), 1 µM, or 10 µM idelalisib for 72 hours. The 
combination of these two inhibitors resulted in an idelalisib-dose-dependent reduction 
of IC50 for nilotinib (Figure 5-20, A). In western blot analyses it was shown, that the 
treatment of K562 cells resulted in the expected dose-dependent decrease of AKT 
phosphorylation, and a slight increase in p27 levels (Figure 5-20, B). 
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6 Discussion 
6.1 CML treatment response to nilotinib correlates with 
PTP mRNA expression 
In the study presented in this thesis, a comprehensive analysis of the potential 
influence of PTPs on the treatment outcome of CML patients was carried out. In this 
screen, we found the expression of PTPRA, PTPRC, PTPRG, PTPRM, and PTPN13 to 
be positively correlated to nilotinib treatment efficiency. In contrast to other reports 
describing effects of PTPs on imatinib treatment (Shimizu, 2004; Koyama, 2006; 
Esposito, 2011; Mitra, 2013; Kok, 2014; Papadopoulou, 2016), our study was designed 
to investigate the influence of PTPs on the more potent second-generation TKI 
nilotinib. Such analyses have previously not been performed. For PTPRA, PTPRC, and 
PTPRM, no reports on a possible role in CML exist. Our study identifies them as 
interesting candidates for studies in CML background. The current aim of CML 
treatment has developed to the point, that not only the control of the disease by lifelong 
TKI treatment is desirable, but to optimize therapy, so that patients can safely stop their 
TKI treatment, and still remain in TFR. In order to do so, a fast and continuing 
achievement of a deep molecular response is required (Mahon, 2002; Mahon, 2010). 
Taking this into account, we chose having a MR4 (BCR-ABL1IS ≤ 0.01 %) after 
9 months of nilotinib treatment as a particularly stringent cutoff point. The ELN 
guidelines define the achievement of MMR (BCR-ABL1IS ≤ 0.1 %) after 12 months of 
TKI treatment as optimal response. In our study, we analyzed the mRNA expression 
status of 38 PTPs in total peripheral blood leukocytes of 66 newly diagnosed CML 
patients. To correlate the influence of a single PTP to the course of disease, two 
patient groups were defined according to whether or not a patient had reached a BCR-
ABL1IS ≤ 0.01 % (MR4) after 9 months of nilotinib treatment. It is remarkable, that the 
pronounced effect of nilotinib appears still modulated by the PTP-status.  
Interestingly, we could not find correlations with response for PTPN1 (Koyama, 
2006), PTPN2 (Shimizu, 2004; Mitra, 2013), or PTPN6 (Esposito, 2011). These PTPs 
were previously reported to have an influence on imatinib treatment. However, 
contradictory findings were published for PTPN2 (Shimizu, 2004; Mitra, 2013; Kok, 
2014) and PTPN6 (Esposito, 2011; Papadopoulou, 2016). One reason for the lack of 
association in our study might be that the more potent inhibitor nilotinib overcomes 
influences of those PTPs. Nevertheless, PTPN6 was still included in functional 
analyses (see below). 
The selection of the 66 CML patient samples was done, not knowing the 
characteristics of the patients, or their treatment outcome, to enable a completely 
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blinded analysis. The only selection criterion was the active participation in the TIGER 
study. After the mRNA analyses had been finished, the patient characteristics were 
analyzed in more detail. Since the TIGER study protocol allowed certain pretreatments 
(TKI, HU), and the actual nilotinib dosing was allowed to be adjusted according to the 
patient’s needs (side effects, adverse events), all available data for each patient were 
re-assessed after unblinding. Two cohorts with sub-sets of patients (n=54 and n=35 
patients) were defined (chapter 5.1), with the n=35 patient sub-group literally having no 
pretreatments, and only minor nilotinib drug dose reductions. In these stringently 
selected sub-sets, the correlation to treatment outcome of the 5 PTPs (found in the 
initial analysis of the n=66 patients cohort) was re-evaluated. Doing so, we aimed to 
exclude influences of the pretreatment that might have already changed the PTP 
mRNA expression level in our analyzed samples, or insufficient treatment responses 
caused by nilotinib dose reductions, that both would compromise our results. PTPRA, 
PTPRC, and PTPRG could be confirmed to be significantly associated to MR4 
achievement after 9 months of study treatment in all sub-groups, supporting the initial 
finding, that these PTPs might play a role in modulating nilotinib treatment response. 
The significance for PTPRM was lost in one of the sub-groups, and for PTPN13, no 
significance could be confirmed in the newly defined patient sub-sets (Figure 5-2, Table 
5-2).  
 Nevertheless, the smaller cohort sizes do limit the statistical power and 
significances could have been overlooked. If the identified PTPs should in the future be 
used as biomarkers for response, it would require additional analyses in larger patient 
cohorts.  
PTPN13 was earlier described in 4 different publications by the same working group 
to be involved in the persistence of CML-leukemic stem cells (LSC) in the bone marrow 
(Huang, 2008; Huang, 2013a; Huang, 2013b; Huang, 2016). They describe PTPN13 as 
a factor contributing to treatment resistance of LSC. An inhibition of PTPN13 in their 
study reduced the LSC persistence (Huang, 2016). This would make PTPN13 a very 
interesting PTP to be followed up, but as the correlation with treatment response was 
lost in the more stringently selected patients, we did further analyze PTPN13 in our 
study. PTPRA, PTPRC, and PTPRG were still significantly associated with treatment 
outcome in all the analyzed patient cohorts, but we decided to continue the functional 
analyses only with PTPRC and PTPRG.   
The analysis of PTP expression can be done using leukocytes of different origin e. 
g. bone marrow aspirates or peripheral blood, and these cells can either be used in 
total, or sub-populations can be selected, thereby focusing on specific cell types, but 
excluding others. Patient cDNA samples derived from peripheral blood were more 
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easily available than bone marrow aspirates. Therefore, we did not include bone 
marrow samples in our study, and focused on peripheral blood samples. A common 
sub-population of leukocytes are PBMCs (peripheral blood mononuclear cells), 
consisting of mainly lymphocytes and monocytes, but not including the multi-lobed 
nuclei-containing granulocytes. Since BCR-ABL1-mediated transformation affects the 
whole myeloid linage and granulocytes are an important and abundant group of CML 
cells, we did not want to exclude them from our study. Initially, all transformation in 
CML arises in HSCs. Therefore, analysis of only CD34+ (a stem cell marker) cells 
would also be a relevant approach.  The advantage of that would be to have a defined 
cell sub-set, more independent from the individual leukocyte composition of each 
patient. Moreover, eradication of CML stem cells is the ultimate aim of the therapy. 
Therefore these cells would be very relevant to assess response or resistance to 
therapy. There are only few CD34+ cells in peripheral blood, thus isolation of sufficient 
cells for our mRNA analysis would have required bone-marrow samples. Therefore, 
these cells appeared not suitable for a large screening project, as they are not isolated 
in standard diagnostic procedures. Taken together, these reasons led us to choose 
total leukocytes from peripheral blood for our screen. As already indicated, the use of 
total leukocytes might lead to false positive or to the concealment of screening hits, 
since the individual percentage of different cell types with specifically high or low 
expression of PTPs might influence the result of our analysis. This was one of the 
reasons why functional, cell based analyses appeared mandatory to evaluate the 
intrinsic influence of selected PTPs on treatment response.   
The PTP-status of the patients was determined only once at diagnosis and not again 
under TKI treatment, as the blood cell counts usually normalize within a few weeks of 
treatment (complete hematologic response), and then, no malignant cells would be 
present in the peripheral blood anymore. An additional analysis of PTP expression 
during nilotinib treatment would therefore reflect the status of a healthy donor and 
would not give any additional information with respect to a role of PTP levels for 
treatment response.  
 
6.2 Experimental conditions to assess TKI responses in 
engineered CML cell lines 
For the functional analyses, a direct assessment of the therapy response was 
chosen: the determination of nilotinib, imatinib, and dasatinib IC50 in cell lines with 
manipulated PTP levels. A similar approach was recently used by Chae et al. in an 
AML study (Chae, 2018). In our study, the engineered cells were treated with a 
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concentration range of the TKIs and the differences in the treatment susceptibility 
between the cell lines that express a specific PTP or not, were measured directly. For 
the specific configuration of these experiments, a number of considerations were 
important:  As the compounds are not stable in aqueous solutions, the dilutions (1:200 
from DMSO stock) had to be prepared fresh for every experiment. Small inaccuracies 
of these dilution steps would influence the resulting IC50, therefore, all the experiments 
of one setup were strictly processed in parallel with the identical TKI dilution, to rule out 
differences caused by preparation of drug dilutions. To measure cell viability, the 
CellTiter Blue reagent was chosen, since it can directly be added to the cultured cells 
and the fluorescence signal can be measured directly without any further solubilization 
steps or medium changes. Mean values of measured fluorescence signals 
(quadruplicate replicas) were the base for the curve-fitting by Sigma Plot (chapter 
4.12). The IC50 is then automatically calculated from this fitted curve. The curve-fitting 
is more accurate, the more values are used. Therefore, selected experiments were 
carried out with more TKI concentrations in the concentration range of the IC50, and the 
corresponding 95% confidence intervals, as markers of the curve-fitting error were 
obtained. In these experiments, the confidence intervals were not overlapping between 
cell lines with different IC50s (Tables 5-4 and 5-6). This proves that the reported 
differences are real, despite being relatively small. By using the Wilcoxon matched-
pairs test for calculating the statistical significance of the differences between the 
engineered cells, we took into account that results obtained in the same experiment 
(identical dilutions) should be compared to each other, since the absolute values might 
have varied somewhat  at different experimental days.  
In order to get insight into the signaling changes that might be involved in the 
alterations of TKI response in PTPRG over-expressing and PTPRC knockout K562 
cells, several signaling molecules were analyzed by western blotting analysis. First, 
BCR-ABL1 auto-phosphorylation (pY245- c-ABL1) was included in the analysis, since 
changes of that would hint on a direct impact of the PTP level change on BCR-ABL1 
activity. STAT5 is constitutively activated by BCR-ABL1 and thereby contributes to the 
transformation of CML cell lines (e. g. K562) (de Groot, 1999). The analysis of the 
influence of PTPRG or PTPRC on pSTAT5 is therefore worth addressing. Since 
PTPRC is a known SFK-phosphatase (chapter 1.2.5), and BCR-ABL1 causes 
activation of SFK, the analysis of the activating phosphorylation of SFK (with an 
antibody detecting pY416-cSRC) was included in the study. The corresponding total 
proteins cSRC and Lyn were chosen since their size exactly matched the three bands 
visible in the phospho-SFK-blots. Lyn kinase has been shown to suppress apoptosis, 
specifically in BCR-ABL1-expressing cells, which makes Lyn an especially interesting 
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protein to study in our context (Ptasznik, 2004).  PTPRG has earlier been described to 
reduce the phosphorylation of ERK 1/2 (Shu, 2010; Xiao, 2014). Also ERK-activation 
occurs constitutively downstream of BCR-ABL1 (Weisberg, 2007).  Thus, ERK 1/2 was 
also included in the signaling analysis. In the study of Shu et al. it was also shown that 
the cell cycle inhibitor p27 was up-regulated in PTPRG expressing breast cancer cells 
(Shu, 2010). This made p27 an interesting candidate for playing a role for the observed 
changes in our analysis of the TKI sensitivity. The anti-apoptotic protein Bcl-2 can be 
successfully inhibited by the compound ABT-199 (venetoclax), which is approved by 
the FDA for treatment of some cases of CLL. As shown very recently by several 
groups, the combination of ABT-199 with TKI can lead to enhanced cell death in CML 
cells (Ko, 2014; Carter, 2016). In addition, BCR-ABL1 can positively regulate the Bcl-2 
family proteins to support cell survival (Brown, 2017). We therefore included Bcl-2 in 
our analysis, to see whether the change in PTP levels would have an impact on Bcl-2 
expression.  
 
6.3 PTPRG promotes TKI responses of CML cells and 
attenuates BCR-ABL1-mediated transformation 
PTPRG was previously reported to be down-regulated in CML patients (Della 
Peruta, 2010; Vezzalini, 2017), and has been described as a possible tumor 
suppressor in other cancer types (Stoker, 2016). In the study presented here we could 
show, that PTPRG is also important in the context of the CML treatment with the 
second-generation TKI nilotinib. The probability of reaching a MR4 after 9 months of 
nilotinib treatment was significantly higher with higher PTPRG levels in the total 
leukocytes at diagnosis in all analyzed sub-cohorts. These differences were robust, 
despite the fact, that PTPRG was one of the PTPs with the lowest mean mRNA 
expression in the analyzed patient leukocytes (Figure 5-1). The mean mRNA 
expression in the analyzed healthy donors was the highest, the level in patients 
reaching an MR4 at 9 months after study treatment was intermediate, and the lowest 
expression level was detected in patients not reaching an MR4 at that timepoint. As 
mentioned above, the use of total peripheral blood leukocytes might lead to false 
positive findings, as the leukocyte composition of the individual blood cell sub-sets 
cannot be taken into account. Different cell types vary in PTPRG expression (Vezzalini, 
2007; Vezzalini, 2017). The same laboratory also presented analyses of PTPRG 
expression (mRNA and flow cytometric analyses) of healthy controls and CML patients 
in bone marrow, PBMCs, peripheral blood, and CD34+ cells, and – interestingly - found 
a lower PTPRG expression in the CML patient samples in all cell populations (Della 
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Peruta, 2010). The flow cytometric analysis of peripheral blood was additionally carried 
out with samples taken from CML patients having a complete cytogenetic response, 
and these samples had, as expected, a similar expression of PTPRG as healthy 
controls, since all CML cells were eradicated by the TKI treatment. In our study, there 
was no substantial correlation of total leukocyte or thrombocyte count, or to the 
percentage of eosinophils, basophils, or blasts with PTPRG mRNA levels (PD Dr. M. 
Pfirrmann, Munich, personal communication). This observation argues against the 
possibility that changes in the leukocyte composition cause the association of PTPRG 
mRNA levels with treatment response.  
In order to find out whether PTPRG does have a direct influence on TKI response, 
K562 cell lines stably over-expressing PTPRG either as the wild type protein, or as the 
phosphatase-dead PTPRG-CS mutant, were established. The over-expressed proteins 
were clearly detectable with a specific PTPRG antibody in western blots. The IC50s of 
nilotinib, imatinib, and dasatinib were determined, and significant reductions of the 
IC50s were found in the PTPRG-WT-expressing cell pools in case of nilotinib and 
imatinib treatment, but not in dasatinib-treated cells. The lowering of the IC50 was 
dependent on the phosphatase activity of PTPRG, because cells expressing PTPRG-
CS did not show a significant reduction of the IC50. The mean reduction of the IC50 in 6 
different nilotinib experiments was 21.3 % for the PTPRG-WT cells compared to the 
empty vector-transduced cells. This change of roughly 20 % might at first sight appear 
small, but applied to the TKI dosing, a reduction of 20 % drug intake could improve side 
effects and diminish adverse events, thereby improve treatment compliance. In 
addition, a dose reduction for selected patients would definitely be an economic 
advantage, if the full therapeutic effect would be maintained. On the other hand, under 
standard dose, patients with high PTPRG level may more readily become eligible to 
stop TKI treatment and achieve a TFR.  
The improved TKI response and earlier studies of PTPRG raise the question of 
possible effects of PTPRG expression on cell proliferation and other aspects of BCR-
ABL1-mediated cell transformation. In our study, no obvious difference in the cell 
growth rate was seen under cultivation, but we did not directly measure cell 
proliferation rates. One other study in MCF-7 breast-cancer cells reported that cell 
growth, and anchorage-independent growth were inhibited dependent on PTPRG-
levels (Liu, 2004). If this was also the case in our CML cell lines, the IC50 determination 
should nevertheless not have been biased, since it was done by calculating the 
individual maximum cell viability in each experiment, and should therefore not have 
been changed by differences in the absolute growth rate.   
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To assess effects of PTPRG on cell transformation, we evaluated the capacity of the 
engineered cells to form colonies in methylcellulose. We found a significant reduction 
(median reduction 35 %) of grown colonies in PTPRG-WT expressing - compared to 
empty vector-transduced cells. This finding is in line with previous reports in CML cells, 
where over-expression of PTPRG in different cell lines led to a colony reduction of 31 – 
40 %. Also, PTPRG-expressing K562 cells had a reduced capacity to grow tumors in 
xenografted nude mice (Della Peruta, 2010).  
To identify potential mechanisms for enhanced TKI sensitivity in PTPRG over-
expressing cells, signaling analyses were carried out. They were performed in two 
different experimental setups: i) in absence of serum in order to get information on the 
influence of PTPRG on BCR-ABL1 signaling only, and ii) in presence of serum either 
with or without nilotinib treatment, similar to the conditions used in the IC50 assays. In 
the absence of serum, a clear reduction of BCR-ABL1 auto-phosphorylation by PTPRG 
over-expression can be detected. This is in line with previous reports (Della Peruta, 
2010). This group also analyzed lysates of K562 cells transfected with full-length 
PTPRG by using total phospho-tyrosine detecting antibodies and found a strong 
reduction of phospho-signal in the lysates of the PTPRG-expressing cells. While the 
total phospho-tyrosine blots did not reveal such striking effects of PTPRG over-
expression (data not shown), we found the phosphorylation of ERK 1/2 to be 
diminished in the PTPRG-WT-expressing cells, in presence, and to a lesser extent also 
in absence of serum. A reduced ERK 1/2 activation upon PTPRG over-expression has 
also been reported by others in a breast cancer cell line or in HEK293 cells expressing 
PTPRG (Shu, 2010; Xiao, 2014). An elevation of p27 as previously reported by Shu et 
al. was in our analysis only seen moderately in presence of serum. Our finding that the 
phosphorylation of the SFK Lyn is reduced in the PTPRG-WT expressing cells was not 
reported earlier. As shown in another study of K562 cells, the specific siRNA-mediated 
down-regulation of Lyn induced apoptosis, specifically in BCR-ABL1 positive cells 
(Ptasznik, 2004). It can be speculated, that the reduction in Lyn-activating 
phosphorylation could contribute to the lowering of the IC50 for nilotinib and imatinib, by 
induction of apoptosis in the PTPRG-WT expressing cells. If that really is the case, 
needs to be further addressed by apoptosis assays in our cell system. It may, however, 
be quite important for the improved TKI response. A simplified scheme, summarizing 
the main findings of PTPRG impact on the analyzed signal-transduction pathways, is 
provided in Figure 6-1. 
As reviewed by Stoker, PTPRG is commonly deleted or down-regulated in different 
cancer entities suggesting that it is acting as a tumor suppressor (Stoker, 2016). The 
findings presented in this thesis argue in the same direction. One common mechanism 
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of PTPRG down-regulation appears to be promoter methylation. Several working 
groups have found PTPRG promoter methylation in different cancer types (Della 
Peruta, 2010; Stevenson, 2014; Xiao, 2014), and that the expression can be induced 
by the use of demethylating agents. Preliminary experiments by ourselves indicated 
that indeed, the combination of TKI with a demethylating agent can lower the IC50 for 
the respective TKI (data not shown). From that experiment alone, however, we cannot 
yet conclude that the induction of PTPRG is the underlying reason for this. To further 
address this question, it would be needed to specifically prevent induction of PTPRG 
expression by knockdown or knockout, and perform the combination-treatment with 
corresponding cell lines.    
We have some evidence that the down-regulation of PTPRG is not a direct 
consequence of the oncogenic BCR-ABL1 signaling, but that BCR-ABL1 actually 
promotes PTPRG expression (data not shown). Long term continuous cultivation (> 6 
months) of cell lines stably expressing BCR-ABL1 led to a decrease in PTPRG mRNA 
and protein expression compared to the starting level (data not shown). The low level 
of PTPRG expression in CML cells might therefore be a result of a long-term selection 
process in BCR-ABL1 addicted cells, potentially driven by a small growth advantage of 
the cells with lower PTPRG expression levels.   
Taken together, we could confirm previous findings of Della Peruta et al. and 
Vezzalini et al., who reported PTPRG to be down-regulated in CML cells and that over-
expression in CML cell lines attenuated BCR-ABL1-mediated transformation (Della 
Peruta, 2010; Vezzalini, 2017). We could expand this knowledge with the finding, that 
PTPRG expression in peripheral blood at diagnosis does positively correlate to fast 
achievement of a deep molecular response in nilotinib-treated CML patients. We could 
additionally show that PTPRG expression directly influences the TKI susceptibility in 
case of nilotinib and imatinib in a phosphatase-activity dependent manner, possibly 
through elevating p27 levels and reducing the activity of Lyn and ERK 1/2.   
 
6.4 PTPRC negatively influences treatment response and 
CML cell transformation 
In our patient analyses, a higher expression of PTPRC was found to be correlated 
with the achievement of a BCR-ABL1IS ≤ 0.01 % after 9 months of nilotinib study 
treatment in the initial analysis of the 66 patients cohort. This correlation was confirmed 
in the subsequent analyses of the more stringently selected patients (Figure 5-2, Table 
5-2). As also seen for PTPRG, PTPRC expression was lowest in the patients not 
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reaching MR4 after 9 months of study treatment, intermediate in the patients that did 
reach MR4, and highest in the healthy donors (Figure 5-1).  
Our study is the first report of PTPRC in the context of CML. In other leukemic 
entities, the role of PTPRC has been addressed but remains unclear. It was described 
as both, an oncogene and as a tumor suppressor. As an example, in T-cell ALL, 
PTPRC was reported to act as a tumor suppressor by negative regulation of Jak/STAT 
signaling (Porcu, 2012). Others found PTPRC expression to be negatively associated 
with survival rates in CLL or B-cell and T-cell ALL samples (Rizzo, 2013; Cario, 2014), 
but these two studies lack functional analyses. 
We decided to include PTPRC in our functional analyses, to gain more information 
on the direct impact of PTPRC expression on the TKI sensitivity in CML cells. As all 
hematopoietic cells express PTPRC, we decided to reduce the expression level by 
shRNA-mediated knockdown. Initial experiments with such cells showed a possible 
influence of the PTPRC expression on the IC50s for the used TKIs (Figure 5-5).  
As the down-regulation by shRNA was not resulting in good knockdown efficiencies, 
we decided to establish CRISPR/Cas9-mediated knockout single cell clones. I was 
able to establish two clones, made by using two different gRNAs (A and B, see chapter 
4.10.1). One of the used gRNAs (A) was covering a part of an intron sequence. This 
enables a successful cleavage of the sequence by the Cas9 nuclease on the genomic 
level, but as this sequence is not fully present in the mRNA of PTPRC we had the 
possibility, to exogenously re-express PTPRC in that particular knockout clone, without 
risking that the stable CRISPR/Cas9 machinery is targeting the introduced sequence. 
The gRNA sequence B is completely located within in the open reading frame. This 
might lead to disruption of the re-introduced PTPRC sequence, which made this clone 
unsuitable for the re-expression of PTPRC. As shown by immunoblots and flow 
cytometry, I was able to generate a cell pool from PTPRC-KO A with rescued PTPRC 
expression levels (KO A + PTPRC) comparable to the control K562 cells (Figure 5-15). 
As control, the PTPRC-KO A clone was transduced with the corresponding empty 
vector (KO A + EV). By using the cells with restored PTPRC levels, we can exclude 
that results obtained using the KO-clone might be clonal effects specific to the selected 
clone, rather than being related to the absence of PTPRC.      
We found that the knockout of PTPRC in K562 cells led to a significant decrease of 
the IC50s for nilotinib and imatinib, and to much lesser extent (not significant for two out 
of three tested cell clones), in dasatinib-treated cells. This effect of the PTPRC 
depletion could be reverted by exogenous re-expression of PTPRC in the PTPRC-
KO A cells, strongly supporting, that the IC50 shift is a direct consequence of the 
absence of PTPRC. These findings indicate, that PTPRC would exert a resistance 
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promoting role, because the cells were more sensitive to nilotinib and imatinib 
treatment in absence of PTPRC. 
The analysis of the BCR-ABL1 driven clonogenic capacity of the engineered cells 
showed that the absence of PTPRC significantly reduced the ability of the K562 cells to 
form colonies in methylcellulose. Unfortunately, the transduction of the empty vector to 
the PTPRC-KO A cells already led to an increased colony formation, but still, this 
elevated colony formation was significantly further increased in cells re-expressing 
PTPRC. This leads to the conclusion, that PTPRC absence diminishes the clonogenic 
capacity of this CML cell line.  
As discussed above (chapter 6.2), an analysis of selected signaling proteins in 
immunoblotting experiments was carried out to find possible mediators of the described 
phenotypes. In the PTPRC-KO cells, a prominent reduction of the catalytic-site 
phosphorylation of cSRC (mean reduction 60 – 80 %) and Lyn (mean reduction 70 – 
80 %) were seen in the absence of serum, and to a lesser extent also in presence of 
serum (Figures 5-18 and 5-19). PTPRC is known to regulate SFK-mediated signaling 
by direct de-phosphorylation of the inhibitory tyrosine residue (Y530 in human cSRC), 
and thereby facilitating the phosphorylation of the active-site tyrosine (see introduction 
1.2.5) (Hermiston, 2009). The absence of PTPRC in our KO cells most likely leads to a 
sustained phosphorylation of the inhibitory tyrosine residue, hampering the full 
activation of the SFK. The re-introduction of PTPRC in the KO A clone led to a clear 
increase in the phosphorylation of the active-site tyrosine, supporting this mechanism. 
For further experiments, it would be of interest, to analyze the phosphorylation of the 
inhibitory tyrosine of these SFKs, to confirm the assumed direct action of PTPRC on 
that residue in our cell model. As already discussed for the PTPRG-WT-expressing 
cells, that also showed a reduced Lyn phosphorylation, we can speculate that this 
activity reduction contributes to the TKI treatment outcome, as the down-regulation of 
Lyn alone (without TKI treatment) already led to induction of apoptosis in K562 cells 
(Ptasznik, 2004).   
In presence of serum, a basal elevation of the cell cycle inhibitor p27 was seen only 
in the PTPRC-KO cells. The treatment of the cell lines with 1 µM nilotinib led to an even 
further elevation of p27 levels. The basal increase of p27 up to about 2-fold in the KO 
cells might in presence of sub-optimal nilotinib concentrations contribute to the effects 
seen in the IC50 assays: the small difference in p27 levels might drive these cells into 
cell-cycle arrest already at lower nilotinib concentrations, compared to PTPRC 
expressing cells.  
The absence of PTPRC slightly increased the phosphorylation of BCR-ABL1, 
indicating that BCR-ABL1 might be a direct target of PTPRC. PTPRC is described to 
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act as a negative regulator of Jak-mediated cytokine signaling by directly binding and 
de-phosphorylating Jaks (Irie-Sasaki, 2001). In our CML cell system, PTPRC might 
negatively regulate BCR-ABL1 auto-phosphorylation, kinase activity, and downstream 
signaling. The phosphorylations of the signaling molecules ERK 1 and 2, downstream 
of BCR-ABL1, were also elevated in absence of PTPRC, indicating that PTPRC might 
act as a negative regulator in this signaling pathway. Nevertheless, to establish BCR-
ABL1 as PTPRC target, additional experiments would be needed: e. g. to show the 
direct interaction of these two proteins, and the PTPRC phosphatase-activity-
dependent decrease of BCR-ABL1 phosphorylation.  
Taken together, absence of PTPRC leads on the one hand to apparently tumor-
promoting changes like increasing BCR-ABL1 auto-phosphorylation and ERK 1/2 
activation, and on the other hand to tumor-suppressive changes by increasing p27 
expression and decreasing SFK activation. In our here-presented cell line model, these 
pathways integrate to an enhancement of TKI sensitivity in absence of PTPRC, 
identifying PTPRC expression as tumor-supporting event. As the SFK inhibition, in 
absence of PTPRC, appears contributing to the treatment sensitization, it is not 
surprising, that the down-regulation of PTPRC does not have such a strong impact on 
the treatment with dasatinib as this TKI also inhibits the SFK. Using this TKI might 
therefore be an advantage for some of the patients that do not have an optimal 
response to nilotinib or imatinib. In Figure 6-1, the here identified actions of PTPRC on 
BCR-ABL1 and its signaling are summarized. 
As it seems favorable to inhibit PTPRC in the CML cells, the use of specific 
inhibitors might be advantageous. Perron et al. introduced a PTPRC selective allosteric 
inhibitor that was able to repress T-cell receptor signals (Perron, 2014). It would be 
very interesting to test this compound in our cell system for the influence on the IC50s of 
the TKIs.    
The results of the functional analyses in PTPRC-KO cells are contrasting to the 
finding in our patient analysis, where a high PTPRC expression-level was correlated to 
a better treatment response. As already mentioned before, the use of total peripheral 
blood leukocytes with unknown cell composition of the individual blood sample might 
lead to correlations which reflect cellular composition rather than intrinsic roles of PTPs 
for treatment response. PTPRC is especially highly expressed in e. g. T-cell-
lymphocytes (Arimura & Yagi, 2010), consequently, a patient sample containing more 
lymphocytes would result in higher PTPRC expression in our analysis. In our study, the 
PTPRC expression level was neither substantially correlated to the patients´ leukocyte 
or thrombocyte counts, nor to the percentage of eosinophils, basophils, or blasts (PD 
Dr. Markus Pfirrmann, Munich, personal communication), but an effect of different 
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cellular composition cannot be ruled out. One other possibility to explain this 
discrepancy is the possibility, that not only the expression level per se is important, but 
the localization of PTPRC within the cells. A study of Saint-Paul et al. reported PTPRC 
to be mis-localized to lipid rafts in AML cells. This led to an increased cytokine 
signaling, that contributed to AML development and maintenance. They found that 
both, down-regulation of PTPRC, or the disruption of the lipid rafts using a 
pharmacologic approach, led to a reduction of leukemia formation in cell lines and 
mouse models (Saint-Paul, 2016). One might speculate that the large amounts of 
PTPRC in primary CML cells are largely mis-localized and therefore unrelated to the 
affects of PTPRC found in the cell line experiments. To investigate a possible role of 
such a localization effect in CML cells, further experiments would be needed.   
PTPRC activity was described to be inhibited by dimer-formation, and that a specific 
PTPRC point- mutation that prevented inhibition by dimer-formation could cause 
lymphoproliferation and autoimmunity (Majeti, 2000). Taking this into account, it might 
be possible that the higher expression level of PTPRC (the PTP with the second 
highest expression in the primary samples of all 38 analyzed PTPs) might lead to an 
Figure 6-1. PTPRG activity and absence of PTPRC attenuate the BCR-ABL1 driven signal-
transduction pathways. Shown here is a summary of the identified actions of either PTPRG over-
expression, or CRISPR/Cas9-mediated knockout of PTPRC on the signaling cascades introduced 
in Figure 1-2. (Left) PTPRG expression leads to an inhibition of BCR-ABL1 auto-phosphoryation, a 
diminished SFK activation, and a reduction of ERK 1/2 phosphorylation. All these effects are 
attenuating the BCR-ABL1 driven transformation. (Right)  The absence of PTPRC has a negative 
effect on SFK activation. Although the absence of PTPRC also promotes the activity of BCR-ABL1 
and ERK 1/2, the net result of the signaling changes in absence of PTPRC is a promotion of 
therapy response.   
Yellow arrows: activation, blue marks: inhibition / inactivation.  
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increased inactivation of PTPRC in cells with higher expression, and that might favor 
the treatment outcome, just as shown in the functional analyses. A direct comparison of 
the PTPRC level per cell in primary samples and K562 cells was not carried out, but 
the mean relative mRNA level in the primary samples was much higher than in the 
K562 cells (Figures 5-1 and 5-3). If an inactivation by dimerization would hold true in 
the patient samples, it may be beneficial to the treatment outcome to further enhance 
or stabilize this state by use of PTPRC dimerization-inducing antibodies, similar to 
previous studies (Spertini, 2004), in addition to TKI treatment.             
 
6.5 PTPN6 does not influence treatment sensitivity in our 
cell models 
Several research groups have found a decreasing level of PTPN6 expression during 
CML progression from CP to BC (Amin, 2007; Li, 2014; Wang, 2017). One additional 
group has investigated a KCL-22 cell line derivative, which was resistant to imatinib 
(KCL-22-R) and found PTPN6 expression to be down-regulated in the resistant cells 
when compared to the imatinib-sensitive (KCL-22-S) counterpart. They exogenously 
over-expressed PTPN6 in the resistant cells, and found a restoration of imatinib, 
nilotinib, and dasatinib sensitivity (Esposito, 2011). A similar phenotype was obtained 
by shRNA-mediated knockdown of the close relative of PTPN6, PTPN11 (SHP2) in the 
KCL-22-R cells: the sensitivity was restored. These two PTPs are very similar in 
structure, but in general have opposing effects on signal transduction (Poole & Jones, 
2005). Therefore it is not surprising that the over-expression of PTPN6 or the down-
regulation of PTPN11 result in similar phenotypes. Unfortunately, these investigators 
did not present an experiment with knockdown of PTPN6 in the sensitive cell line, 
which would support their statement of PTPN6 being the main factor for resistance 
development. Nevertheless, we decided to follow up on this concept and included 
PTPN6 in our cell analyses. This was done although we did not find a correlation of 
PTPN6 expression with treatment outcome in our patient samples. However, PTPN6 is 
relatively abundantly expressed, and silencing of gene expression in different 
hematopoietic cancers had been reported (Hendriks & Böhmer, 2016). The first 
experiments we carried out employing shRNA-mediated knockdowns of PTPN6 in the 
parental KCL-22 cells, followed by the analysis of IC50 changes as discussed above. 
Using two different shRNAs, we obtained knockdown efficiencies of 50 – 70 %, but the 
IC50 analyses did not give a clear cut result, they varied in different experiments. 
Therefore, we decided to knockout the PTPN6 gene to obtain more reliable results. 
Two established KO clones were again analyzed, but still, no obvious difference in TKI 
 Discussion - 72 - 
 
sensitivity was found. Then K562 cells, that are expressing very little PTPN6, were 
used to over-express PTPN6-wild type or the phosphatase-dead PTPN6-CS mutant. 
Despite good over-expression levels of PTPN6, again no substantial changes in the 
TKI sensitivity of the engineered cells were seen.  
An earlier study of Papadopoulou et al. tried to find a prognostic relevance of 
PTPN6 in CML patient samples (Papadopoulou, 2016). They observed a trend of a 
lower PTPN6 expression in non-responding CML patients, but could not find significant 
correlations of PTPN6 level with treatment outcome, similar to our findings presented in 
this thesis.          
We can conclude from our experiments that PTPN6 is not directly responsible for 
the TKI sensitivity in the CML background. The fact that the KCL-22-R cell line 
investigated by Esposito et al. had a lower PTPN6 level may therefore rather present 
an alteration caused by the clonal selection of the resistant cells than being the cause 
of the resistance itself. The key experiment (knockdown of PTPN6 in the sensitive cell 
line) was not shown in their work, but was now provided in this thesis. It revealed that 
the absence of PTPN6 alone does not substantially influence the TKI sensitivity. Since 
PTPN6 is a known negative regulator of cytokine signaling (Hendriks & Böhmer, 2016), 
it can be speculated, that an abrogation of cytokine signaling caused by the lack or the 
over-expression of PTPN6 in those cells causes the described phenotypes. PTPN6 
down-regulation in advanced stages of CML might indicate that the abrogation of the 
cytokine signaling is contributing to the progression of the disease, but as our 
experiments have shown, presumably not because of a direct influence on the inhibitor 
sensitivity.  
 
6.6 Implications for therapy optimization and 
combination-treatments    
The cell cycle inhibitor p27 is stabilized and thereby up-regulated by the inhibition of 
the PI3K-signaling pathway. Idelalisib, a specific inhibitor of PI3Kẟ was approved for 
the treatment of CLL. Chen et al. have used idelalisib in combination with imatinib to 
treat K562 cells (Chen, 2016) and found an accumulation of p27. We have combined 
the PI3K-inhibitor idelalisib with the TKI nilotinib and assessed the influence of this 
combination on the IC50 for nilotinib in K562 cells (Figure 5-20). As expected, the 
combination of the two drugs led to a reduction of the IC50 for nilotinib. This is a proof of 
principle that the findings presented in this thesis may help to find new therapy 
approaches, or find co-treatments that support and complement the standard TKI 
treatments. The results obtained in this thesis revealed several possible starting points 
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for therapy optimization. These include the induction of PTPRG expression using 
demethylating agents, the inhibition PTPRC by cross-linking antibodies or inhibitors, 
the elevation of p27 (e. g. by treatment with idelalisib), as well as the inhibition of SFK 
(e. g. by using dasatinib). All this might prove helpful in order to further optimize TKI 
treatment response in CML patients and thereby improving the chances of some CML 
patients to reach a functional cure of the disease. Moreover, findings in this thesis may 
in the future be used to either establish new prognostic markers, or help to identify 
patients that are eligible to safely reduce TKI dosage.  
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8 Abkürzungsverzeichnis 
ABL1 Abelson Murine Leukemia Viral Oncogene Homolog 1 
AKT v-akt murine thymoma viral oncogene homolog, identical to PKB 
ALL acute lymphoblastic leukemia 
AML acute myeloid leukemia 
AP accelerated phase 
BC  blast crisis 
Bcl-2 B-cell lymphoma 2 
BCR  breakpoint cluster region  
BCR-ABL1 oncogenic fusion protein of BCR and ABL1 
CA domain carbonic anhydrase-like domain 
CCyR complete cytogenetic remission 
CLL chronic lymphocytic leukemia 
CML chronic myeloid leukemia 
CP chronic phase 
CRISPR/Cas  
clustered regularly interspaced short palindromic repeats/CRISPR-
associated protein 
crRNA CRISPR RNA 
CS mutation of the catalytically active cysteine to serine 
Csk C-terminal SRC kinase 
cSRC cellular homologue to v-src expressed by Rous Sarcoma virus 
DSB double-strand DNA break 
dsRNA double-stranded RNA  
e. g. exempli gratia, for example 
ELN European LeukemiaNET  
ERK extracellular signal-regulated kinase 
et al. et alii, and others 
FCS fetal calf serum 
FDA US Food and Drug Administration  
FISH fluorescence in situ hybridization 
FLT3-ITD  Fms-like tyrosine kinase 3 with internal tandem duplication 
FN domain fibronectin-like domain 
gRNA guide RNA  
HDR homology-directed repair 
HIV human immunodeficiency virus 
HSC hematopoietic stem cell 
HU hydroxyurea 
IC50 half-maximal inhibitory concentration 
IFN-α interferon-α  
IQR interquartile range 
IS international scale 
Jak2 Janus kinase 2 
KO knockout 
Lck lymphocyte-specific protein tyrosine kinase, p56Lck, a SFK 
LSC leukemic stem cell 
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Lyn Lck/Yes related novel tyrosine kinase, a SFK 
MEK MAP- and ERK kinase 
MR4 deep molecular response with a BCR-ABL1IS ≤ 0.01 % 
mRNA messenger RNA 
NHEJ Non-homologous end-joining 
P/S penicillin/streptomycin 
p27 CDKN1B, cyclin-dependent kinase inhibitor 1B, also p27Kip1 
p56 identical to the SFK Lck 
PCR Polymerase-chain reaction 
PEG-IFN-2αb  pegylated interferon α2b 
PI3K phosphatidylinositol-3-kinase 
PKB protein kinase B, identical to AKT 
PTK protein-tyrosine kinase 
PTP protein-tyrosine phosphatase 
pY phospho-tyrosine 
RISC RNAi –induced silencing complex 
RNAi  RNA interference 
ROS reactive-oxygen-species 
RPTP receptor-like protein-tyrosine phosphatase 
RT-qPCR  reverse transcription- quantitative PCR 
SCID severe combined immunodeficiency 
SFK SRC-family kinases 
SFM serum-free medium 
SH2 domain SRC homology 2 domain 
shRNA small hairpin RNA 
siRNA small interfering RNA 
TFR treatment-free remission 
TKI tyrosine-kinase inhibitor 
WT wild type 
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